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Drug development is a long-lasting, complex, expensive and highly regulated process. 
International ethical and scientific quality standard “Good Clinical Practice” (GCP) defines 
roles and responsibilities of sponsors and investigators conducting clinical trials. Sponsor 
may transfer trial-related duties and functions to Contract Research Organizations (CROs). 
Outsourcing clinical trials to CROs has been growing trend since 1980s and outsourcing is 
estimated to continue in the future. Cooperation between sponsors and CROs is followed 
in yearly surveys, but there are only few studies about cooperation between investigators 
and CROs.  
 
The purpose of this qualitative research is to increase knowledge about cooperation be-
tween Investigators and CROs. Aim is to describe how investigators are experiencing co-
operation with CROs by finding out what kind of positive and negative experiences investi-
gators have in cooperation between investigators and CROs. Data was collected from in-
depth interviews of six physicians who had over five year experience in the field of clinical 
trials and had experience in cooperation with CROs.  Data was analyzed by using conven-
tional content analysis.  
 
Results showed that investigators had positive experiences especially in cooperation with 
trial monitor (CRA). Positive experiences were related to situations where CRA was work-
ing together with trial site personnel, CRA was qualified and CRA was working in business-
like manner. Negative experiences related to cooperation with CRA were related to situa-
tions where CRA´s working methods were not satisfactory and site was left alone with in-
creased workload. Investigators also reported experiences that were related to CRO´s 
position and operational environment. Experiences were related to situations where CRO 
was using sites to get profit, CRO-sponsor contract caused difficulties, CRO´s working 
methods were not satisfactory and how operational environment influences in cooperation.  
 
Results of this research increase knowledge about cooperation in clinical trial field. Results 
help to identify development needs in cooperation between investigators and CROs and 
these can be used to improve procedures related to investigator – CRO cooperation.  
Keywords Cooperation, clinical trial, investigator, contract research or-
ganization 
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1 Introduction 
 
Drug development is a long-lasting, complex, expensive and highly regulated process. 
It takes approximately 10 years from finding a suitable compound to the market author-
ization of a new drug (Alkio 2012:13). During those years pharmaceutical company 
needs to conduct clinical trials to provide substantial evidence of drug’s safety, effec-
tiveness and efficacy. Clinical trials that involve participation of human subjects are 
conducted according to international ethical and scientific quality standard “Good Clini-
cal Practice” (GCP) guideline (Azoulay - Repenning - Zuckerman 2010: 474). Principles 
of GCP are implemented in EU legislation in EU directives 2001/20/EC and 
2005/28/EC and in Finnish legislation in Medical Research Act 488/1999 and in Finnish 
Medicine Agency (Fimea) Administrative Regulation “Clinical Trials on Medical Prod-
ucts” 2/2012.  
 
Good Clinical Practice defines roles and responsibilities of two important actors in clini-
cal trials; sponsor’s and investigator’s. According to GCP (1996) “A sponsor may trans-
fer any or all sponsor’s trial-related duties and functions to a CRO, but the ultimate re-
sponsibility for the quality and integrity of the trial data always resides with the spon-
sor”. Due to expensiveness of a long clinical trial phase in drug development, pharma-
ceutical companies have been seeking for lower costs and higher effectiveness. From 
the mid-1980s clinical research outsourcing has increased meaning that pharmaceuti-
cal companies (sponsors) have transferred increasing amount of their trial-related du-
ties to contract research organizations (CROs) (Azoulay et al 2010: 474). According to 
Petryna (2011) CROs are the biggest and most profitable sector in clinical trial industry.  
 
The other vital party in putting clinical trials in practice is the investigator. As stated in 
GCP (1996) the investigator is responsible of conducting the clinical trial at the trial site. 
The sponsor is responsible for selecting investigators and monitoring that trial is con-
ducted in compliance with approved protocol, good clinical practice and local regula-
tions. The activities contracted out to CROs from the start of the trend of outsourcing 
have been recruiting, coordinating, monitoring and supervising the investigators. (Azou-
lay et al 2010: 474; Petryna 2011: 954) 
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Finland has a long tradition and good reputation as an interesting country for pharma-
ceutical companies to conduct clinical trials. However, the number of clinical trials and 
the number of participants in clinical trials in Finland are decreasing. Lack of resources 
in healthcare has decreased the opportunities for doctors to participate in clinical trials 
as investigators. Participating in drug development has also wider effects: via participa-
tion doctors familiarize themselves with new therapies and novel medicine, patients are 
able to get new therapies and research offers also incomes and work to other compe-
tent people (for example study nurses) in hospitals, universities and companies (Phar-
ma Industry Finland 2014c). Ministries in Finland have also set a goal for growing by 
2.5 times by 2020 in pharmaceutical and health technology sector (Työ- ja elinkeino-
ministeriö 2014, 1). 
 
There has been research about relationship and cooperation between sponsors and 
CROs. Many publications indicate that co-operation is often complicated and both par-
ties have been dissatisfied with partnerships. Cooperation between sponsor and inves-
tigator is also important for successful clinical trial, but this partnership has not been 
studied. Because the most of the pharmaceutical companies have outsourced spon-
sor’s activities which are done at the clinical trial site and in collaboration with investiga-
tors, it is important to find out how investigators are experiencing this “third party” part-
nership.  
 
Purpose of this Master’s Thesis is to find out how investigators in Finland are experi-
encing cooperation with contract research organizations in a field of clinical trials. Aim 
is to find out what kind of positive and negative experiences investigators have in co-
operation with CROs. Results may help in identifying development needs in CRO op-
erations and in cooperation between investigators and CROs.  
 
2 Theoretical Background 
 
2.1 Clinical Trial 
 
Developing a new drug to the markets is an intensive, expensive and long-lasting pro-
cess. Only one of 10000 product ideas is approved on the markets and research pro-
cess takes 10-15 years. Estimated cost of the whole research and development pro-
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cess is approximately 1,1 Milliard Euros. In drug development the focus is on individu-
alized treatments and only one out of ten medicines makes profit which covers costs of 
the development process. (Alkio, 2012: 13-14.) Figure 1 describes the drug develop-
ment process from the start to the end. In this thesis the focus is on clinical trial phase 
in which drugs are tested on human trial subjects.  
 
 
Figure 1. Drug development process 
 
2.1.1 Definition of Clinical Trial 
 
Good Clinical Practice (1996) is an international, ethical and scientific quality standard 
for trials which involve the participation of human subjects. The guideline should be 
followed while conducting clinical trials or other investigations that may have impact on 
safety and well-being of human subjects and are intended to be submitted to regulatory 
authorities. The definition of a clinical trial in GCP (1996) is “any investigation in human 
subjects intended to discover or verify the clinical, pharmacological and/or other phar-
macodynamic effects of an investigational product(s), and/or to identify any adverse 
reactions to an investigational product(s), and/or to study absorption, distribution, me-
tabolism, and excretion of an investigational product(s) with the object of ascertaining 
its safety and/or efficacy”.  
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In Medical Research Act 488/1999 in chapter 1, section 2 clinical trial means “interven-
tion research on persons for the purpose of finding out effects of medicinal product in 
human being as well as its absorption, distribution, metabolism or excretion in the hu-
man body”.  In Fimea administrative regulation (2012) clinical trial is defined as an in-
terventional study conducted with human subjects in order to discover the effects of 
medicinal products in human subjects or their pharmacokinetics in the human organism 
or both.  
 
Before a clinical trial can start in Finland a favourable opinion from Ethics Committee 
(EC) and approval from Finnish Medicine Agency (Fimea) must be obtained. In case 
Fimea has not requested additional clarifications and 60 days from commence of trial 
evaluation process has past, trial can be started without a specific approval from 
Fimea. Also notifications of termination or completion of clinical trial and summary of 
trial results are provided to Fimea and EC within timelines given in the legislation. Once 
a year during the time clinical trial is ongoing in Finland, sponsor is obligated to provide 
Fimea and EC a list of occurred suspected serious adverse reactions and evaluation of 
overall safety aspects of trial. Report is signed by a person responsible for the trial. The 
person responsible for the trial in Finland is selected by the sponsor and is a physician 
or dentist with adequate professional and scientific qualifications. The person responsi-
ble for the trial ensures that personnel conducting trial is competent and conditions are 
safe and all local and international legislations are taken into consideration during the 
clinical trial process. (Fimea 2012, 13; Laki lääketieteellisestä tukimuksesta 488/1999). 
 
2.1.2 Field of Clinical Trials in Finland 
 
Research and science have always had an important role in Finnish welfare. High edu-
cational level has guaranteed competence and expertise, good patient registers are 
available and Finnish people have had a positive attitude towards research operations. 
Finland has a long tradition in clinical trials and international pharmaceutical companies 
have valued operational environment and competence in Finland in clinical trial sector. 
(Alkio 2012, 9)  
 
Pharma Industry Finland (PIF) is following statistics in clinical trials and as noticed in 
figure 2, number of ongoing clinical trials in Finland has decreased since 2008. Also the 
number of people participating in clinical trials as clinical trial subjects has decreased 
as presented in figure 3. In 2014 approximately 82% of initiated clinical trials in Finland 
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were sponsored by pharmaceutical companies and 70% of trials notified to Fimea were 
international multicentre trials meaning that trial is conducted according to the same 
protocol but in different trial sites and by more than one investigator in different parts of 
the world (Fimea 2015).   
 
 
Figure 2: Ongoing clinical trials conducted by PIF member companies in Finland (modified from 
Pharma Industry Finland 2014b) 
 
 
Figure 3. Number of participants in clinical trials in Finland without vaccine trials (Modified from 
Pharma Industry Finland 2014a) 
 
Factors influencing to decrease in amount of clinical trials in Finland can be catego-
rized to three groups. At first Finland has lost competitive position as an attractive 
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Eastern Europe, Asia and South America, because those areas have potential phar-
maceutical markets and price-quality ratio has improved. (Lääketeollisuus 2012: 12-13; 
Smed – Getz 2014: 2; Vogel – Getz 2009) 
 
The position of investigators in Finland is also challenging. Experienced investigators 
are aging and junior doctors are less motivated to participate in clinical trials as investi-
gators. Junior doctors may not have competence in research because educational 
training focuses to patient care. Health care environment has also decreased time and 
personnel resources from medical research field. Lack of encouragement and the level 
of compensation is demotivating. Also the increased use of CROs in clinical trial man-
agement has transferred trials to countries where CROs have strong networks. 
(Lääketeollisuus ry 2012: 14-16) Centralizing functions as a trend among international 
pharmaceutical companies may lead to situations where Finland is seen as a part of 
Nordic countries rather than an independent player (Työ- ja elinkeinoministeriö 2014: 
21). Patients in Finland have had positive attitude towards participation in clinical trials, 
but this attitude is also changing. Participation in clinical trials is time-consuming and 
people have access to health care and medications also without clinical trial participa-
tion. (Lääketeollisuus ry 2012: 16)  
 
The second category concerns the growing trend towards non-intervention studies 
(NIS). Non-intervention trials are typically studies which are done after medicine has 
been approved to markets (phase IV trials). Trial data in non-intervention studies is 
usually collected from patient databases, registers and interviews. Differing from many 
other countries, in Finland interviews have been construed as intervention and trials 
that include interviews need to have same kind of approval procedures as traditional 
phase I – III clinical trials. This construction together with a difficult access to patient 
databases and strict data privacy policy has ruled Finland out from NIS markets. Third 
reason for decreasing number of clinical trials in Finland is difficulties in business and 
finance environment in Finland. Number of new enterprises in research sector has de-
creased. Entrepreneurship is not supported in academic environment, lack of peer 
networks and business knowledge make starting processes burdensome and difficult. 
(Lääketeollisuus ry 2012: 18-20) 
 
According to Alkio (2012) despite of competence in research sector, Finland has not 
succeeded in wide-scale commercialization of this knowhow. Possibilities of growth in 
pharmaceutical sector are potential in both employment and economical point of view. 
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In 2010 there were five pharmaceutical companies among “top 10” organizations in-
vesting to research and development (R&D). To get Finland back to a desired country 
of investments for pharmaceutical companies the Finnish Ministry of Social Affairs and 
Welfare, the Ministry of Employment and Economy, the Ministry of Education and Cul-
ture, The Finnish Funding Agency for Innovations (TEKES) and Academy of Finland 
published a growth strategy of research and innovation in health sector (Työ- ja 
elinkeinoministeriö 2014). The purpose was to identify development needs in innova-
tion ecosystem in order to get competitive advantage for Finland as an attractive busi-
ness partner in health sector. The strategy points out the global nature of R&D sector. 
Global networking among research communities and markets and the role of entrepre-
neurs in commercialization are vital factors also when national ecosystem is regenerat-
ed. The aim is to get 20% annual growth in national and international research invest-
ments and to get private investments increase 2, 5 times during next ten years in Fin-
land.  
 
2.2 Sponsor 
 
Definition of Sponsor in GCP (1996) is “an individual, company, institution or organiza-
tion which takes responsibility for the initiation, management and/or financing of a clini-
cal trial”. In Finland every clinical trial must have a sponsor. In case an outside party 
only participates in financing clinical trial, investigator and financing party may agree 
that investigator takes care of responsibilities of the sponsor. (Laki lääketieteellisestä 
tutkimuksesta 488/1999 §2.) 
 
Sponsor is responsible for utilizing qualified personnel to supervise the conduct of the 
trial, to handle and verify the trial data, to conduct the statistical analysis and to prepare 
trial reports. The sponsor should designate medical personnel to advise on trial related 
medical questions or problems. Prior to start of any clinical trial, sponsor should ensure 
that safety and efficacy data from preclinical studies are available to support human 
exposure and to evaluate safety of investigational product on the ongoing bases. The 
sponsor ensures that investigational products are properly manufactured and trans-
ported. The sponsor also provides instructions to the proper handling and storage of 
products and maintains a system for the disposition of unused investigational products. 
(GCP 1996.) 
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Sponsor’s responsibility is to select investigators who conduct the clinical trials (GCP 
1996). U.S. Food and Drug Administration (FDA 2013) have recommended the factor’s 
sponsors should consider when selecting investigators for the clinical trials. Previous 
experience with investigator and site, workload of the investigator and study staff and 
resources available at the study site should be considered. Key components when ini-
tiating clinical trial at site are ensuring that investigator and site staff understand re-
sponsibilities, study process and procedures, regulatory requirements and sponsor’s 
process for monitoring the clinical trial.  According to GCP (1996) to verify that rights 
and well-being of trial subjects are protected, reported data is accurate, complete and 
verifiable from source documents and trial is conducted in compliance with approved 
protocol, GCP and regulatory requirements sponsor should appoint monitors for the 
trial and ensure that the trial is adequately monitored. It is sponsor’s responsibility to 
determine appropriate extent and nature of monitoring.  A monitor, usually called Clini-
cal Research Associate (CRA) as job title, should be familiar with investigational prod-
uct, the trial protocol, informed consent form and other written information to be provid-
ed to the subjects, sponsor’s standard operating procedures (SOPs), GCP and regula-
tory requirements. The monitor is the main link of communication between the sponsor 
and the investigator. GCP defines responsibilities of the monitor and the monitor should 
submit a written report to the sponsor after each trial related contact with the investiga-
tor.  
 
Regulatory authorities, European Medicine Agency (EMA) and U.S. Food and Drug 
Administration (FDA), have published guidelines for risk-based quality management in 
clinical trials on 2013. Increasing costs, complexity of clinical trials, variability in investi-
gator experience, trial site infrastructure, treatment choices and standards of health 
care and increasing use of electronic systems and records have created new challeng-
es to clinical trial oversight and quality management. (European Medicine Agency, 
2013; FDA, 2013.) 
 
Monitoring is one of the quality control tools. Traditionally sponsors have conducted on-
site monitoring visits at approximately 4-8 weeks interval with 100% verification of all 
data at the trial site. On-site monitoring has been used to identify missing data and dis-
crepancies between source data and data provided to the sponsor, to verify that source 
documentation exists, and to assess the quality of processes. On-site visits have 
played important role in training and in providing feedback to trial personnel. Increased 
use of electronic records and technical solutions has made increasing amount of clini-
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cal trial data remotely available. Therefore recommendations of centralized and risk-
based monitoring approach have been issued. The idea is to focus on the most critical 
data elements and processes to achieve study objectives, decrease on-site visits and 
direct on-site visits to the higher risk sites. Resent evaluations have suggested that 
centralized monitoring can identify the most of the on-site monitoring findings. The use 
of routine review of submitted data, statistical analysis to identify data trends and ana-
lyzing site characteristics can help in identifying significant concerns, higher risk clinical 
sites and ensure human subject protection and data quality across trial sites. (Europe-
an Medicine Agency, 2013; FDA, 2013.) 
 
In global survey (Avoca 2014) both sponsors and CROs reported the use of data driven 
approaches in clinical trial activities. Greater portion of CRO respondents reported 
making at least moderate advances of it over the past two years in clinical trial activities 
than sponsor respondents. A majority of sponsor respondents indicated that CROs are 
making significant or essential contributions to the use of data driven approaches in 
four key areas: site selection, region selection, monitoring and patient recruitment. 
CROs acknowledged that sponsors have contributed their adoption of new data driven 
approach by helping them to understand general approaches and by making data 
available. Although significant advancements were made in the movement towards 
more data driven approaches in clinical trials, additional progress is needed to realize 
the full potential of new approaches. Both sponsors and service providers should de-
velop tailored strategies to guide investments in this area with clear priorities regarding 
capabilities needed in-house and with those that are best fulfilled via cooperation with 
service providers like CROs.  
 
Time optimization in a long and expensive clinical trial process may narrow sponsor´s 
focus on ongoing trials and especially on patient recruitment and data collection phase 
of the trial. Post-trial initiatives and interaction are not utilized as effectively as possible. 
Post-trial communications between trial partners like investigators and CRO represent-
atives could give a possibility to share general reflections and feedback about the trial. 
Current cooperation processes and increased management layers including integrated 
CRO partners restricts valuable knowledge-transfer between sponsors and investiga-
tors. Due to restrictions investigators are not able to get enough information about the 
final outcome of the trials and sponsors are not able to develop processes or identify 
opportunities for optimizing future and ongoing trials. Feedback could also reveal in-
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formation about user´s experience in investigative product that might be relevant for 
clinical practice in future. (Smed – Getz 2013: 80-85; Smed – Getz 2014: 1.) 
 
2.3 Investigator 
 
Investigator is a person responsible for the conduct of the clinical trial at a trial site. 
Investigator should be qualified by education and experience and provide evidence of 
such qualification to assume responsibility for the proper conduct of the clinical trial. In 
case trial is conducted by a trial team, investigator is the responsible leader of the 
team. The responsible leader is usually called as “Principal Investigator”. Principal in-
vestigator should maintain a list of the personnel at the trial site to whom she/he has 
delegated trial-related duties. Investigator should be able to demonstrate availability of 
potential suitable trial subjects and adequate staff and time resources to conduct trial 
properly and safely. Investigator is responsible for trial-related medical decisions and 
also ensures that adequate medical care is provided to the trial subject. (GCP, 1996.)  
 
Investigator should conduct clinical trial in compliance with an approved protocol. Devi-
ations from the protocol should be agreed with the sponsor and ethics committee be-
forehand unless deviation is made to eliminate immediate hazard to trial subject. All 
deviations should be documented and explained. Prior to the participation in clinical 
trial, written informed consent should be signed and dated by the subject or the sub-
ject’s legally representative and by investigator or a person designated by investigator 
who conducted the informed consent discussion. Copy of the informed consent form 
should be provided to the subject. Exceptions and variations from this process should 
be described in protocol and to be approved by Ethics Committee. (GCP 1996.)  
 
According to GCP (1996) investigator is responsible for investigational products at the 
trial site, including storing products according to instructions from the sponsor, keeping 
records and inventory of the products and ensuring investigational products are used 
only accordance to an approved protocol. Investigator is also responsible for explaining 
the proper use of products to trial subjects and he/she should check that instructions 
have been followed. Investigator is responsible for data and safety reporting to the 
sponsor. Data should be consistent with source documents and according to Finnish 
legislation (Fimea, 2012: 14) clinical trial documents must be archived at least for 15 
years.  
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Clinical trials are typically conducted in two different type of clinical trial sites; academic 
and independent. Trial site types differ from organizational structure and incentives for 
conducting clinical trials.  Independent trial sites are specialized in conducting clinical 
trials. As the trial site personnel are not occupied with daily clinical practice, they are 
highly professionalized around clinical trial processes. At the academic trial sites per-
sonnel are often engaged also in other activities related to the health sector. Academic 
trial sites have previously dominated the clinical trial environment, but over the last 20 
years industrialization of site organizations has been globally observed. (Smed – Getz 
2014: 2)  
 
Investigators and investigative sites are important actors in drug development process 
as they may have input into study design, they have access to trial participants and 
they are also a critical source for information about clinical practice experiences. Partic-
ipating in clinical trials offer opportunities for investigating doctors to learn more about 
novel medication and learn how to apply drug after launching. (Smed – Getz 2013: 80; 
Smed – Getz 2014: 1.) Investigators have indicated that primary motivator to partici-
pate in clinical trials as investigator is an opportunity to be involved in the research of 
innovative medical treatments. Research has shown that older investigators who had 
participated in high percentage of CRO managed trials preferred working directly with 
sponsor. Other investigators had no preference or they preferred more CROs. (Glass, 
2009.).  
 
Turnover rate among investigators conducting clinical trials is significant. Globally 35 – 
55% of investigators gave up doing research after first clinical trial and this fact in-
creases and escalates costs of sponsors for site selection, qualification and training of 
new investigators and trial start-up. Reasons for turnover rate may be categorized for 
three groups: 1) system and organization related 2) Trial related and 3) Physician re-
lated reasons. System and organization related reasons include time needed for re-
search-related work, discussions with patients, grant applications, costs, facilities and 
infrastructure and requirements of sponsor. Trial related reasons include lack of ra-
tionale for the research, increasing complexity of trials, costs not covered by sponsor 
and inferior trial drugs compared to standard therapy. Physician related reasons in-
clude lack of interest in the research topic, unfamiliarity with trial procedures, lack of 
support staff and disruption to clinical practice. Investigators have reported completing 
contractual and regulatory documents, recruiting patients, budgeting and getting paid 
on time, completing feasibility surveys and reporting adverse events as the most bur-
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densome activities in clinical trials. Also interacting with trial monitors, tracking clinical 
supplies and retaining patients in the study were burdensome especially for inexperi-
enced investigators. (Cascade – Sears – Nixon 2015.) 
  
2.4 Contract Research Organization (CRO) 
 
Contract Research Organization is a person or a commercial, an academic or other 
organization contracted by the sponsor to perform sponsor’s trial-related duties and 
functions. Although the sponsor transfers duties and functions to CRO, the ultimate 
responsibility for the quality and integrity of the trial data resides with the sponsor. 
(GCP 1996.) In Guidance for Industry FDA (2013: 18) recommended that sponsor and 
CRO prospectively establish a clear understanding of responsibilities and expectations 
for the conduct of transferred obligations. An appropriate process of relevant and timely 
information sharing should be in place. 
 
2.4.1 Outsourcing Clinical Trials  
 
History of CROs can be traced to the pharmaceutical expansion after World War II. 
Outsourcing of sponsor’s duties and functions has increased enormously since 1990s. 
It was estimated that over 90% of pharmaceutical companies had outsourced at least 
some of the clinical trial activities by 1993. In 2010 largest pharmaceutical companies 
outsourced almost 100% of Phase IIIB and IV trials and laboratory services to CROs 
and service providers. Use of CROs in all therapeutic areas and clinical trial phases 
increased 44% between 2007 and 2011. (Bryde – Joby 2007: 364; Henderson 2013; 
Petryna 2011: 953-954.) 
 
According to Tarnainen (2012) in 2009 there were 26 CRO companies operating in 
Finland. 15 companies were founded in Finland and all of them in western countries. 
Based on the information on trade register 22 of 26 CROs had less than 50 employees. 
According to the companies’ websites the most common services CROs in Finland 
provided were regulatory support, medical writing, training, clinical trial monitoring, pro-
tocol writing, data management and project management. Same activities are the most 
outsourced also globally (Vogel – Getz 2009).   
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The main reasons for increased outsourcing are high and rising costs of clinical phase 
of drug development. Pharmaceutical companies face challenges and competition. 
Therefore ability to reduce and share risks and uncertainty are drivers for outsourcing. 
Companies are seeking ways to manage clinical trials more effectively and efficiently 
and to introduce new drugs faster to the markets. Pharmaceutical companies also aim 
to focus to their core competence: marketing medicinal products. Outsourcing of re-
search and development has become a management issue, because formerly R&D 
has been seen as a part of business that should always be kept in-house, but now the 
boundaries of the companies are coming more open. Outsourcing of at least those 
parts of R&D that are not seen as core activities has become possible and even inevi-
table. (Bryde – Joby 2007: 363; Tarnainen 2011: 7-8; Suomi 2012; Vogel – Getz 2009.)  
 
Clinical trials are transferred to countries where treatment naïve population is available. 
People in western countries are saturated with treatments and produce too many drug-
drug interactions. This makes them less usable for showing effectiveness of a specific 
drug. (Petryna 2011; Vogel – Getz 2009.) By outsourcing clinical trial activities, phar-
maceutical companies are able to expand their area of operations without need to es-
tablish permanent premises in countries (Tarnainen 2011: 8). For smaller companies 
outsourcing is needed to get access and flexibility to required staff and skills as they 
cannot afford to build up their own internal resources (Contract Pharma 2014; Mehta – 
Peters 2007: 30; Suomi 2012; Vogel – Getz 2009).  
 
Outsourcing of R&D has also risks. Outsourcing company may come dependent on the 
supplier and loose knowhow and overall market performance. (Suomi 2012.) At the 
moment pharmaceutical companies are downsizing R&D departments and as a result 
the expertise and the knowledge about clinical trial management is increasingly going 
outside the companies. In this situation CROs are able to hire professionals who come 
directly from pharmaceutical industry and know how to conduct trials the way sponsor 
companies want to handle them. (Reese 2011.) Integration of CROs to clinical trial pro-
cesses may also compromise relationship between sites and sponsors as the previous 
direct relationship has been changed to more distant relationship (Smed – Getz 2013: 
84). 
 
In literature two types of outsourcing are defined in field of clinical trials; strategic and 
tactical outsourcing. Tactical outsourcing is a variation of fee-for-service contracts and 
more short-term and used on a project-by-project basis. Tactical outsourcing refers to 
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transactional and opportunistic relationship between the sponsor and CRO. Strategic 
outsourcing involves formal long-term partnership with selected CRO/CROs. The aim is 
to build partnership based on trust, form closer ties and business integration, share 
objectives and build long-term business stability and save money. Trend among spon-
sor organizations is to develop relationship with CROs to more strategic outsourcing 
approach. (Bryde and Joby 2007: 364-365; Contract Pharma 2014; Henderson 2013; 
Smed – Getz 2013: 84; Vogel – Getz 2009). 
 
The four elements that characterize strategic outsourcing are (1) close link between the 
outsourcing processes and the key success factors of the company, (2) transfer of the 
ownership of a previously internalized business function, (3) long-term commitment and 
contract between company and supplier, (4) existing contractual definition of obliga-
tions and service level (Suomi 2012). Four most important attributes for strategic part-
nership in 2013 were history of quality, cultural fit, partnership philosophy and cost. The 
most important service provider overall not just strategic attributes were overall value, 
prior positive experience with the provider, risk management, project management 
quality, therapeutic expertise and contingency planning. (Henderson 2013.) 
 
2.4.2 Sponsor – CRO Relationship 
 
Despite the outsourcing type, the sponsor – CRO relationship is vulnerable to problems 
where interest of pharmaceutical company and CRO may be misaligned and both par-
ties act in their own best interest (Bryde - Joby 2007: 364-365). Azoulay et al (2010) 
from Massachusetts Institute of Technology showed that despite the efforts to build 
embedded relations between a pharmaceutical company and CRO, relations were 
chronically underperforming, adversarial and short-lived. Level of commitment from 
sponsors to their contract organizations was a critical factor which was often missed by 
sponsor’s managers. Firms were dealing with large number of CROs and they were 
constantly changing suppliers. This reflected the situation of negative commitment and 
was demotivating to the CRO partner to make investments specific to client or satisfy 
client-level demands. Feelings of mistrust impacted to pharmaceutical firms’ assess-
ment of the chronically underperforming CROs. Perception of underperformance led to 
the need for ongoing monitoring of CRO teams and increased costs and decreased 
effectiveness. The sponsors have been dissatisfied with oversight of service providers, 
the governance of quality, communication and availability of quality personnel for pro-
jects and efficiency and timeliness in achieving clean data (Avoca 2011). 
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Results (Azoulay et al 2010) also showed that internal and external clinical trial per-
sonnel were allocated to the trials in different ways. In-house monitors at sponsor firms 
were assigned to single project at the time and it was very likely that the same monitor 
(CRA) with experience of the drug was assigned to follow-up study as well. External 
CRO monitors were assigned to multiple projects, multiple clients and shifted across 
the projects as needed. These working practices allowed in-house monitors to have “a 
sense of project ownership” and in contrast perception of uncommitted CRO monitors. 
Sponsors still expected the same level of loyalty and performance from temporary CRO 
staff than from their own permanent staff. Unrealistic and unreasonable expectations 
led to disappointment and mistrust. The practice of using CROs to fill in the employ-
ment caps was not officially announced although it was publicly recognized. The drug 
development process is predicated on the idea that clinical trials are impervious to the 
influence of non-medical factors. It would be problematic for sponsor to admit that or-
ganizational arrangements may have influenced to data production and outcomes of 
clinical trials. Trend to invest towards higher-level strategic partnership has improved 
satisfaction. Sponsor organizations have realized that CROs are not just extension of 
staff but really a part of the clinical research team and high-level relationship is possible 
only if there is mutual respect, cooperation and honesty. (Henderson 2013; McKay - 
Syrop - Calaprice-Whitty 2011.)  
 
In terms of quality, sponsors have been satisfied with CROs compliance with written 
procedures, data quality and integrity and audit plans and execution. Sponsors are 
more comfortable with quality in Western and Central Europe and North America than 
in Asia, Latin America and Africa. It is noted that service providers assume they are 
providing higher quality than sponsor feels they receive. Main causes for issues with 
quality and gap in perception between sponsors and providers seems to be cost pres-
sures on the industry and inability of providers to consistently perform to their potential 
due to constraints placed by sponsors. (Avoca 2011.) If CROs are paid and punished 
according to task-specific schedule, attention of CRO monitors is directed from 
knowledge production to data-processing and speed of execution of tasks. Therefore 
CRO employees have been characterized as “data mules” that receive less training 
and are overworked. This may lead to burnout and turnover. A high turnover rate of 
CRO monitors has been issued among sponsors. (Azoulay et al. 2010.)  
 
One key finding in study of Azoulay et al. (2010) was difference in the information flow. 
CROs relied on formal reporting mechanism and the information was likely to be lost or 
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get filtered before it reached the sponsor. Information flowed more freely in pharmaceu-
tical companies. Communication and information sharing seem to be areas where im-
provement is still needed. According to Contract Pharma (2014) survey, sponsors are 
expecting more proactivity and feedback from CROs about their processes and meth-
ods to be able to improve functions. They also describe lack of transparency in com-
munication and they hope that service providers share also mistakes and problems 
with them in time. CROs are complaining that they do not get enough information from 
the sponsor to get work done properly. They would like to get more upfront information 
from the sponsor. 
 
Mixed communication channels between sponsors, CROs and investigators create 
insufficient and poor information and knowledge flow. Trial site personnel are com-
municating simultaneously with managers from sponsor and CRO, CRAs and sales 
department representatives. Diffused communication channels hinder the development 
of personal and engaged professional relationship which may improve and encourage 
free flow of both tacit and formal information. Designation of single point of contact may 
create clear information flow structure and ensure knowledge transfer more efficiently. 
(Smed – Getz 2013: 85-86.) 
 
Early and complete integration of CRO into clinical trial program, proactive quality 
management for example the use of written quality agreements, setting up effective 
governance and oversight structure and setting up metrics to measure performance are 
seen as factors that ensure quality and optimal performance and increase sponsor´s 
overall satisfaction with work performed by CRO (Avoca 2011; McKay et al 2011). 
CROs desire to have more input to protocol design and planning state of clinical trials. 
Sponsors still prefer outsourcing trial execution although early partnership offers bene-
fits. One of the benefits is better communication and collaboration between sponsor 
and CRO. Early partnership allows establishing a dialog that enables both parties to set 
realistic expectations and to build trust. Collaborative environment gives the ability for 
CRO to take ownership and accountability with decisions and actions and contribute to 
each component of clinical trials. CROs are also experts in study management and 
have a hands-on knowledge about the clinical trial sites due to ongoing relationship 
with the sites. This gives an opportunity for CROs to evaluate a protocol logistically and 
see if study is doable. Early cooperation also enables sponsors and CROs to prepare 
flexible and realistic budgets. (Reese 2011.)   
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2.5 Cooperation  
 
Working together with someone or with another company or organization to the same 
goal or to achieve something are definitions given to word “cooperation” (Oxford dic-
tionary, 2014; Cambridge Dictionary 2014). Also a synonym word “collaboration” is 
commonly used in English literature when writer is describing situation where people 
are working together to create, achieve or produce something. Cooperation was cho-
sen as a key word for this research, because in business language definition refer also 
to “being willing to be helpful and to do what someone asks you to do” (Cambridge Dic-
tionary, 2014). Cooperation involves decision making among interdependent parties, 
joint ownership of decisions and collective responsible for outcomes (Peters – Manz, 
2007: 119). 
 
Cooperation has been researched from many scientific perspectives and it is a chal-
lenging phenomenon which has been understood in many ways. Cooperation is con-
textual as context guides the nature and appearance of cooperation. (Aira, 2012: 30.) 
In this research cooperation between people working in different organizations; clinical 
trial sites and CROs is in focus. Interorganizational cooperation can be seen as a set of 
communicative processes where individuals representing different organizations work 
interdependently (Keyton – Ford – Smith, 2008: 381). The focus in this research is on 
organizational representatives not in organizations. In this type of cooperation individu-
als are responsible to their organizations and have organizational resources. These 
factors influence what messages surface. Representatives may not have a prior rela-
tionship and they must develop structures and processes for creating relationships, 
identifying goals, sharing information and making decisions. (Keyton et al 2008: 381.) 
In the context of this thesis CRO representative has a complexed role; she/he is repre-
senting two organizations, the sponsor and CRO to investigators.  
 
According to Aira (2012) communication in interpersonal relationships creates shapes 
and maintains cooperation and the same definition is used for cooperation in this re-
search. In cooperation shared goals are inevitable and communication is needed to 
find the shared goals. Cooperation is a voluntary choice and purposive and active col-
laboration process originates from need and desire to create something new or resolve 
a problem. The process is dynamic and requires active input from both participants. 
One of the most important factors in cooperation is trust. Trust is built in interaction. 
Disagreements and problematic situations may reduce trust, but successful problem 
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resolving may increase it. When people are cooperating and interacting, they become 
dependent on each other. Too close or too distant interactive relationship may be 
harmful for cooperation. If an individual in cooperation system is changed, there is a 
need to build a new relationship and trust with new representative. (Aira, 2012: 132-
136.) 
 
In the context of clinical trials investigators and CRO representatives are interacting 
and cooperating both face-to-face and by technologically mediated collaboration. As 
mentioned in chapter 2.2, the trend is to decrease on-site visits to trial sites and to in-
crease usage of technological solutions in the sponsor – investigator cooperation. 
Modern technology enables interaction and collaboration, but it does not guarantee it. 
In hectic work life and busy schedules, tasks with deadlines are prioritized and com-
munication with business partners decreases. Active communication is also required in 
a dispersed cooperation. For a successful cooperation, a good interpersonal communi-
cation is more important than the geographical location of parties. (Aira, 2012: 143-
145.)   
 
3 Purpose, Aim and Research Objectives 
 
A worldwide trend is to increase usage of Contract Research Organizations in conduct 
of clinical trials. The purpose of this Master’s Thesis is to increase knowledge about 
cooperation between Contract Research Organizations and investigators in the field of 
clinical trials. The results of the research will help CROs to identify development needs 
and to improve procedures related to clinical trials and cooperation. The aim of the re-
search is to describe how investigators in Finland are experiencing cooperation with 
Contract Research Organizations. Objective is to find out answers to following research 
questions:  
 
1.) What kind of positive experiences investigators have in cooperation with 
CROs? 
2.) What kind of negative experiences investigators have in cooperation with 
CROs? 
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4 Materials and Methods 
 
4.1 Research Method 
 
This research has a qualitative approach and conventional inductive content analysis is 
used as data analysis method. In content analysis data is describing the phenomenon 
and intention is to find meanings from the fragmental data and describe those mean-
ings in an explicit and compact way. Inductive content analysis is a three phase pro-
cess including reduction of data, clustering data and abstraction of data. (Tuomi – Sa-
rajärvi, 2013: 104 – 108). Data analysis process of this research is described in chapter 
4.5 Data Analysis.  
 
4.2 Sampling 
 
The purposive sampling technique was used in this research. In qualitative research 
persons chosen as sources have experience and/or knowledge in theme under re-
search and based on their expertise researcher expects them to provide the best pos-
sible information (Tuomi – Sarajärvi, 2013: 86; Pitkäranta, 2010: 114). To find out the 
experiences about cooperation with CRO companies, I asked permission to interview 
doctors working with clinical trial from one private health care provider, Hospital District 
of Pirkanmaa and Hospital District of Helsinki and Uusimaa, although working organi-
zations of interviewees are not revealed in Master’s Thesis. After a discussion with 
coordinator of Hospital District of Helsinki and Uusimaa I decided to leave investigators 
from that hospital district out from this research due to complicated approval and inter-
view request processes.  
 
After getting approvals, interview request letters in Finnish (appendix 1) were sent via 
email to 10 potential interviewees during 08Jan2015 - 03Feb2015. Criteria for selection 
were at least five years’ experience in clinical trials and experience in collaboration with 
CRO. Receivers of the interview request letters were selected from my investigator 
contacts gathered during eight years working experience in clinical trial field as Clinical 
Research Associate and I also got some recommendations from colleagues’ and two 
interviewees recommended their colleagues’. According to Eriksson and Kovalainen 
(2008: 52) it is quite a legitimate alternative in business research to conduct research 
with the people that are familiar to researcher or at least have direct or indirect contact 
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with them. I obtained six answers via email with interest to participate in this research 
and face-to-face interviews were scheduled for convenient time and place chosen by 
investigators. Due to interviews I spent 33 hours in buses and travelled 2330 kilometres 
across Finland. 
 
4.3 Data Collection 
 
To collect investigators’ experiences in cooperation with CROs, six in-depth face-to-
face interviews were performed during 15Jan2015 – 19Feb2015. To give an opportuni-
ty for interviewees to express themselves with the most natural way, interviews were 
performed in Finnish. Times and places for interviews were chosen by interviewees. In-
depth interview was chosen as it is a research technique to reveal a vivid picture of the 
participant’s perspective on the topic under research. It is a non-structured method and 
the only topic of the interview defined and questions are open-ended. During in-depth 
interview conversation and questions are related to purpose and aim of the study and 
research question. (Mack - Woodsong - MacQueen - Guest - Namey 2005: 29; 
Pitkäranta 2010: 107; Tuomi - Sarajärvi 2012: 75.) 
 
In the beginning of the appointment I told interviewees briefly what and where I am 
studying and the purpose of my research. They were able to ask questions if they 
wanted to. I told them that I have no specific questions or themes which we need to go 
through, but the purpose was that they can freely, openly and honestly tell me what 
kind of positive and negative experiences they have in cooperation with Contract Re-
search Organizations. I told that during the conversation I may ask some specifying 
questions. I also informed that all names and places revealed during interview are 
masked when I write interviews word by word to my computer. This was important for 
two reasons: first was to keep anonymity and second reason was that interviewees 
were able to speak openly without a need to be worried about their expressions. I told 
that interview is recorded with the recording application in my mobile phone. Before 
starting interview and recording, interviewee and I signed informed consent form (ap-
pendix 3).  
 
The duration of the interviews varied from 33 to 60 minutes and all together I obtained 
5 hours in recordings. I transcribed recordings word by word within 3 days from the 
interview and obtained 50 pages of written material in Arial font 11 and with line spac-
ing 1,5. I evaluated data collection as successful. After four interviews I began to see 
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that same kinds of experiences were repeated in the interviews. In that point I had al-
ready made appointments for two more interviews and I decided not to send new inter-
view requests until I have made six interviews to see if the data really is repeating itself 
and it can be assumed that new interviews will not provide new information for the re-
search. After six interviews I was confirmed that this sample was appropriate and satu-
ration had been fulfilled as described by Tuomi and Sarajärvi (2012: 87).  
 
During the interviews I focused on listening and did not make any written notes, but 
after every interview I made notes about the atmosphere during interview and what 
was my impression about the interview session as whole. Based on those notes, the 
atmosphere in interview sessions was cosy and trustful as interviewees were able to 
reveal their experiences openly and honestly. Five out of six interviewees were investi-
gators I had had prior work relationship during some point of my career in clinical trial 
field. I noticed that investigators with whom I had worked for several years and we were 
quite familiar with each other, it was more difficult to keep conversation in a topic and 
theme of this research. In those situations I needed to guide interview more to keep it 
on a theme. After listening to interviews many times from the recorder I evaluated that I 
managed to do that quite professionally and early enough, so most of the time the in-
terviews were focused on the research questions.   
 
4.4 Data Analysis 
 
After every interview I listened to recording ones or twice before I transcribed it literally. 
I printed transcriptions and read them once or twice to get an impression and overview 
about the data as a whole. After reading the data, I started to underline sentences and 
phrases (group of words from one or more sentences standing together as conceptual 
unit) that answered to my research questions. I copied those underlined sentences and 
phrases to separate document and these became meaning units of the research data. I 
reduced meaning units to include only relevant for the research. These condensed 
meanings were listed on a separate document that included all condensed meanings 
from every interview. I gave different colours for all interviewees so I was still able to 
follow from which interview listed meaning was originally taken from.   
 
After reduction I started to make theme clusters from condensed meanings. In this 
point I did not separate positive, negative or neutral meanings, but I grouped all mean-
ings concerning the same theme together. After first clustering I printed documents out 
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and read them through. In some cases I went back to original interview to check that 
the theme group was correct. During that process I made some regroupings. After I 
was satisfied with theme groups, I started to group condensed meanings in theme clus-
ters according to my research questions and gave names to created subcategories. I 
continued to cluster subcategories to categories and from categories I abstracted three 
themes to describe my research subject; “Positive experiences related to cooperation 
with CRA”, “Negative experiences related to cooperation with CRA” and “Experiences 
related to CRO position and operational environment”. 
 
 
Figure 4: Data reduction process in numbers  
 
After processing data to themes, I once again went back to the original interviews and 
read them through to verify that I had not missed anything and that themes were de-
scribing original data. Data reduction was also checked by an instructor. Few minor 
changes in condensed meaning clustering were made due to these check-ups.  
 
5 Results 
 
5.1 Background Information of the Interviewees 
 
Due to a limited number of potential interviewee the anonymity is a challenge. There-
fore minimal background information was collected from the investigators. Six inter-
viewed doctors were specialist physicians representing five different therapeutic areas. 
3  
themes 
9 categories 
44 subcategories 
302 condensed meanings 
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One interviewee was female and five were males. Interviews were conducted in five 
different towns in Finland. Five interviews were conducted at a private clinic and one in 
a public hospital. Four out of six interviewees had experience in clinical trials from both 
private and public sector and two had only experience from private clinics. Experience 
in clinical trial field varied from 8 to 35 years and all interviewees had been in a role of 
Principal Investigator in clinical trials operated by CRO. 
 
Most of the investigators told spontaneously about their motivations to be involved in 
clinical trials. From the rest of the investigators I asked about their motivators. All of the 
investigators told that most motivating factor was to be in the frontline, ability to see 
what new is happening. Clinical trials gave doctors an opportunity to learn more about 
disease and therapeutic area for which a new drug is developed for and an opportunity 
to familiarize themselves to novel therapies. Based on knowledge gained from clinical 
trials they already knew how the drug is functioning, how to use it and for which patient 
group it is most suitable for when the drug is on markets.  
 
“Tykkään olla siinä niinkun etulinjassa ja nähdä, että miten lääke toimii ennenkun 
se on apteekissa, et sit kun se on apteekissa mä tiedän ihan tarkalleen, et siihen 
on tullut sellanen hunch et kelle potilaalle kannattaa juuri kyseistä lääkettä edes 
kokeilla… tää on niin jollain tavalla kiehtovaa” (Interview 2) 
 
“I like to be in frontline and see how medicine is functioning before it comes 
available in pharmacy, so when it is available in pharmacy I know exactly, I have 
got a hunch to which patients this particular drug is even worth to try… This is 
somehow fascinating” (free translation) 
 
Doctors also saw clinical trials as the only safe way to get new medicines available to 
patients. Some of the doctors felt that it was an ethical duty of the doctor and hospital 
to participate in treatment development so that novel and better treatments will be 
available for the patients. Clinical trials gave also variation to basic practice and long 
and intensive patient-doctor relationships in clinical trials were rewarding. 
 
5.2 Collecting Positive and Negative Experiences during Interviews 
 
I started all the interviews by asking when interviewee has started working in the clini-
cal trial field and have they noticed the trend to increase CRO usage in clinical trials. In 
most of the interviews investigators started to share their opinion and experiences in 
cooperation with CROs without further questions. Most of the investigators started with 
negative experiences. I noticed that in all interviews there was no need to ask about 
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negative experiences, those were expressed spontaneously. When I asked about posi-
tive experiences some of the interviewees thought that there must be some positive 
experiences, but they were not able to recall them as the negative experiences were on 
the top of their minds. But eventually all the interviews included both positive and nega-
tive experiences. Although many negative experiences were shared, investigators ex-
pressed that they do not bear ill will to anyone or want to harm no one. They expressed 
regret at lack of positive experiences. Like one of the interviewed investigator ex-
pressed:  
“Tarkoitan sitä, ettei oo tarkotus tuottaa kellekään mitään vaivaa tai pahaa mieltä, 
mutta jokainenhan meistä tulkitsee maailmaa omien kokemusten pohjalta ja ko-
kemukset on tän tyyppisiä ni ei siltä voi välttyä” (Interview 3) 
 
“I mean that there’s no intention to cause any trouble or give offence to anyone, 
but every one of us interpret world through our own experiences and if experi-
ences are like this, it cannot be avoided” (free translation) 
 
I understood that it was also in investigators interest to develop cooperation to more 
positive direction and that is why they expressed that this research was important. In 
following chapters I will describe investigators´ experiences by themes obtained from 
data analysis. 
 
5.3 Positive Experiences Related to Cooperation with CRA 
 
Cooperation with CRA was understandably the most discussed topic during interviews. 
CRA is the main contact between investigator and sponsor and CRA may be the only 
sponsor representative that has face-to-face contact with investigator and other site 
personnel during clinical trial project. There were altogether 88 condensed meanings 
describing positive experiences related to cooperation with CRA and these were clus-
tered to 11 subcategories and to three categories (Figure 5). 
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 Theme: Positive experiences related to cooperation with CRA 
Categories: 
1) CRA is working 
together with 
trial site per-
sonnel 
2) CRA is qualified 3) CRA works in a 
businesslike 
manner 
Subcategories: 
CRA is ready to help CRA is a specialist  Monitoring is done in 
a businesslike man-
ner 
Tasks are handled 
together 
CRA is an insider in 
pharmacompany 
Decrease in monitor-
ing frequency is not 
problematic 
Mutual understanding Enough training is 
available  
Communication and 
information flow 
smoothly 
Tasks are handled 
properly 
Personality effects on 
cooperation 
Figure 5. Positive experiences related to cooperation with CRA: theme, categories and subcat-
egories 
 
5.3.1 CRA is Working together with Trial Site Personnel  
 
The first category in the theme “Positive experiences related to cooperation with CRA” 
is derived from four subcategories; CRA is ready to help, Tasks are handled together, 
Mutual understanding and Communication and information flow smoothly.  
 
Investigators expressed in interviews that in their point of view it is CRA’s duty to help 
them with problems and questions. Investigators have the most positive experiences in 
cooperation with CRAs who are helpful, willing to help and who assist site personnel 
and resolve issues. 
 
“Semmonen monitori on hyvä, josta niinku heti huomaa, et se on niinku avulias ja 
valmis auttamaan, koska ainahan tulee semmosta kysymistä. Et se on niinku se 
ensimmäinen, et siel on se valmius auttaa ja ratkaista ongelmia, jos ei heti jollain 
puhelinsoitolla tai muulla selviä, niin sit se selvitetään seuraavana päivänä tai sit 
joka tapauksessa.” (Interview 4) 
 
””From the good monitor you can right away notice that she/he is helpful and 
ready to help, because there will always be questions, That is the first thing that 
there is a willingness to help and resolve problems, if not right away by phone or 
some other way, the issue will be resolved on a next day or eventually anyway.”  
(free translation) 
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Investigators wanted to describe clinical trials as a cooperation project and teamwork 
where CRA and site personnel are planning and executing trials together. They had 
positive experiences related to face-to-face meetings in the initiation phase of trial, 
where operational plans are settled and agreed together with CRA. During the trial ex-
ecution investigators were satisfied if problems were resolved together and corrections 
for documents and trial data were discussed and corrected in cooperation with CRA. 
Investigators wanted to have CRA’s assistance and guidance to be able to do their own 
part of the duties correctly.  
 
“Ne tehdään yhdessä. Normaali käytäntö on niin, että se monitori, niin aamulla 
yleensä sen nään kun se tulee jos suinkin on mahollista ja sitten mä tuun muu-
taman tunnin päästä käymään ja sitten tarkistetaan ne liput ja laput ja ne korja-
taan samaan aikaan yhdessä, niin sillon mä tiedän millä tavalla tää ihminen ha-
luaa tän homman hoitaa ja sitten se on niinkun kerralla pois päiväjärjestyksestä.” 
(Interview 6) 
 
”Those are done together. Normal procedure is that I meet the monitor usually in 
the morning when she/he arrives if possible and then I come few hours later and 
we check notes and post-its and we correct them right away together. That is the 
way to see how this person wants to handle these tasks and then they are han-
dled correctly right away.” (free translation)  
 
Successful clinical trials are conducted in a good cooperation. A good collaboration 
motivates investigators and site personnel to do their best in patient recruitment and 
data generation. It also motivates investigators to participate in new, future trials and in 
that way it also has an impact on amount of trials running in Finland in future. 
 
Investigators experienced that mutual understanding about clinical trials as cooperative 
project is important. They wanted CRA to tell what kind of expectation CRA, CRO and 
sponsor have on them. One of the interviewees said that sharing CRO’s aims and ob-
jectives could help investigators to understand why certain metrics, timelines and sta-
tistics are important for CRA´s organization. It would help investigators and CROs to 
understand collaborator’s perspective and help to achieve goals together. 
 
“Mun mielestä ihan site initiation visitin yhteydessä vaan niinku näytettäis, että 
mitkä on niinku CRO-firman ja sponsorin tavotteet… ja sitten tota mitkä on niin-
kun toimeksiantajan kannalta tärkeet asiat… Et avattais tavallaa se kortti: tähän 
me pyritään ja tää ois niinkun meijän kannalta optimaalista niin se vois avata tut-
kijan silmiä, et ai jaa, no eipä tullu mieleenkään.” (Interview 2) 
 
“In my opinion during site initiation visit one should show objectives of CRO and 
sponsor… and what is important in a sponsor’s aspect… So someone shows the 
cards: this is our goal and this would be optimal for us. That might open investi-
gator’s eyes that ok, I did not even think about that” (free translation) 
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All the interviewees shared an experience that CRAs are easily available by telephone 
and email and contacts with CRA have been successful. Issues were usually resolved 
on telephone. Situations where CRA was not reached were rare. Contacts with CRA 
were principally satisfying and investigators felt no need to have contacts with sponsor 
personnel if communication with CRO-CRA was functioning. If there were some disa-
greements, they were resolved in discussions.  
 
In situations where CRA was changed during trial execution, investigators felt that in-
formation from former CRA to new one was transferred, at least if change was planned 
and CRAs had possibility to work together for some time before actual trial handover. 
Although information was transferred there might have been a sort of uncertainty peri-
od before the new CRA had full knowledge about the trial, but according to interview-
ees it did not generally effect on cooperation or cause problems. Investigators also 
thought that it was depending on person how given information was processed and 
used. A CRA change may have also positive effects on trial. In long projects the new 
CRA may energize and inspire site personnel to continue in the project with new en-
thusiasm.   
 
5.3.2 CRA is Qualified 
 
Second category in theme “Positive experiences related to cooperation with CRA” is 
derived from two subcategories; CRA is a Specialist and CRA is an insider in pharma-
company. Investigators brought out appreciation for CRA’s competent in trial manage-
ment. They indicated that working with a competent and acquainted CRA makes coop-
eration easier and motivates trial site for better performance. Qualified CRA has 
knowledge in trial processes and management, therapeutic area, other diseases and 
medications. With qualified CRA misunderstandings and false interpretations of source 
data are avoided. Investigators felt that it is important to ensure CRAs competent in the 
beginning of the trial process and this is the responsibility of CRO and sponsor. 
 
“Monitoroijan asiantuntemus on kans ihan tärkeä. Että on semmonen kokemus 
monitoroijallaki niin sehän on suureks avuks. Siis tämmösen tutkimuksen vetämi-
sestä, myös tietysti sen meneillä olevan tutkimuksen sisällöstä ja muusta, mut 
sen lisäks kuinka ne tutkimukset hoidetaan ja erityisesti ne semmoset ongelma-
tapaukset, et sielt tulee vastaus heti niin sitä kyllä minä arvostan” (Interview 4) 
 
“Monitor´s competent is also important, it is big help if monitor has experience in 
leading clinical trial and also in content of ongoing trial and other things, but also 
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about clinical trial management and specially how to handle issues, so that reso-
lutions come right away. That´s what I appreciate” (free translation) 
 
To get proper competence and acquaintance, investigators thought that CRA needs to 
be somehow inside in a pharmaceutical company or at least insider position has bene-
fits. In insider position the CRA is able to get general view of the drug development 
process. The commitment and acquaintance of pharmaceutical company to certain 
therapeutic area or molecule enables insider to get more information about the subject 
in focus. In situations where CRA from CRO is working as in-house CRA in a pharma-
ceutical company there is no difference between sponsor’s own CRAs and CRO-CRAs 
in aspect of cooperation. Investigators were satisfied with in-house CRA arrangement.  
 
“Vaik mä en tiedä mist firmasta on vuokrattu, mut sit on se etu, et on sisemmällä 
siinä firmassa, että ei oo niinku päälle liimattu tämmönen niinku välikappale, joka 
joutuu aina kysyy kaiken firmasta vaan on sisällä siinä ja pystyy ihan omiakin no-
peita ratkasuja heittää, jos tulee jotain ongelmia, et se on mun mielestä ihan toi-
miva systeemi.” (Interview 2) 
 
“Although I don’t know from which firm she/he is contracted, but there is a benefit 
that she/he is inside in firm, that she/he is not just an obvious connecting piece, 
who needs to ask everything from the firm, but she/he is insider and able to make 
own decisions in situations where issues appears. In my opinion, this system is 
practical.” (free translation) 
 
5.3.3 Work is done in a Businesslike Manner 
 
The third category in theme “Positive experiences related to cooperation with CRA” is 
derived from five subcategories; Monitoring is done in a businesslike manner, De-
crease in monitoring frequency is not problematic, Enough training is available and 
Tasks are handled properly, Personality effects on cooperation. In the interviews inves-
tigators expressed satisfaction towards monitoring visits conducted by CRA. They felt 
that monitoring visits have been generally conducted in business-like manner and there 
were no differences between CROs. All the interviewees were experienced investiga-
tors and they felt that decrease in amount of monitoring visits is not influencing in co-
operation and is not a problem for an experienced investigator and site personnel. 
Monitoring visit frequency could be prolonged if trial site was familiar with clinical trial 
processes and CRA was available for technologically mediated communication. For 
inexperienced investigator decrease in visits may cause increased workload.  
 
“Siinä ei o nyt ollu kauheesti ongelmaa, varmaan liittyy kokemukseenki. Mä tie-
dän ne tavalliset sudenkuopat, tiedän mitä kirjataan ja näin poispäin, ettei tuu hir-
veesti töitä, vaikka tääl CRA ois pari päivää paiskis töitä… Mut vähemmän koke-
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neelle se voi olla, et tota sit tulee niin hirveesti kirjattavaa ja korjattavaa ja muuta 
tämmöst näin niin niinku nääkähtää siihen ja sit motivaatio laskee.” (Interview 2) 
 
“It´s not problematic, it may be related to experience. I know the usual pitfalls, I 
know what to document and so on, so it does not cause lots of work although 
CRA is working here for couple of days… But for less experienced it may be. 
There will be so much recording and correcting and other that kind of tasks and it 
causes exhaustion and then motivation decreases.” (free translation) 
 
The interviewed investigators were quite satisfied with the training they have received 
for the clinical trials. Trainings are increasingly done via internet instead of former face-
to-face investigator meetings and investigators experienced some benefits in this 
change. Trainings via internet are available for completion at any convenient time. 
Overall experience was that training obtained via internet and during site initiation 
phase by CRA was enough at least for experienced investigators. Investigators were 
satisfied with increased frequency in monitoring visits in the beginning of the trial. It 
prevented systematic error occurrence and gave opportunities for further training. Ben-
efits of global or local investigator meetings were networking and ability to practical 
training and guidance.  
 
Cooperation between investigators and CRAs is an interpersonal cooperation between 
two personalities and chemistry between personalities influences on cooperation. Per-
sonality effects on working methods of both collaborators and also to attitude to work 
and quality of work. Investigators stated that difficulties due to unfitting chemistry were 
not dependent on company or professional skills, it was purely related to persons. Alt-
hough personal characteristics have influence on cooperation and willingness to coop-
erate investigators appreciated that duties and tasks were performed in cooperation in 
a business-like manner. Professional attitude towards collaborators including open and 
decorous communication was functional. The most important thing was that work is 
done properly. Overall experience of the investigators was that with most of the CRAs 
chemistries have matched and there were only rare individual cases where differences 
in personalities have caused major problems.  
 
“Tutkiminen on työtä ja tota työtovereihin suhtaudutaan niinkun työtovereihin suh-
taudutaan elikkä asiallisesti ja ammatillisesti ja se yleensä toimii kauheen hyvin” 
(Interview 2) 
 
”Research is work and work colleagues are treated as workmates; properly and 
professionally and it works usually very well” (free translation)   
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5.4 Negative Experiences Related to Cooperation with CRA  
 
Attitude of interviewed investigators towards CRAs was appreciative and positive but 
they shared also negative experiences related to cooperation with CRA. There were 82 
condensed meanings describing negative experiences related to cooperation with CRA 
and these were clustered to 13 subcategories and two categories (figure 6).  
 
Theme: Negative experiences related to cooperation with CRA 
Categories: 
1) CRA´s working method 
is not satisfactory 
2) Site is left alone with in-
creased workload 
Subcategories: 
CRA is not committed to re-
solve issues  
Tasks are transferred to sites 
CRA is not completing tasks CRA is lacking knowledge 
CRA is task oriented CRA is not helping 
CRA is lacking service attitude Resolving technical problems is time 
consuming 
Contacts are pending Lack of personal guidance 
CRA´s working method is an-
noying 
Practical training for technology is 
needed 
CRA gives only negative feed-
back to site 
Figure 6: Negative experiences related to cooperation with CRA: theme, categories and subcat-
egories 
 
5.4.1 CRA’s Working Method is not satisfactory 
 
The first category in theme “Negative experiences related to cooperation with CRA” is 
derived from seven subcategories; CRA is not committed to resolve issues, CRA is not 
completing tasks, CRA is task oriented, CRA is lacking service attitude, Contacts are 
pending, CRA´s working method is annoying, CRA gives only negative feedback to 
site.  
 
Investigators were disappointed and frustrated in situations where CRA was not com-
mitted to resolve issues related to trial. There were differences between CRAs in level 
of engagement and commitment. Investigators had experienced that CRO-CRAs were 
not as committed and engaged as sponsor’s own CRAs. Based on their experiences 
monitors of CROs did not have time or motivation to solve issues. It was not in CRAs’ 
interest to further affairs in timely manner. CRAs did not take responsibility or owner-
ship on trials and tasks they were involved in. Investigators gave a reason for lack of 
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commitment and motivation from outsider position of CRO-CRA; if the CRA is not able 
to see the whole picture she/he is not seeing the effect of actions or lack of actions to 
wholeness. 
“Kun tulee joku ongelma eteen, sen selvittäminen sujuu helpommin kun on täm-
mönen sitoutunut ihminen, joka sit ymmärtää, et tää pysähtyy nyt tää prosessi, 
jos ei tätä asiaa hoideta ja sillon se vaikuttaa siihen myös ajallisesti. kun taas tää 
CRO ulkopuolinen ihminen sille ei merkitse niin paljon kuin hyvin ajallisesti ja 
asiallisesti se asia sujuu vaan hän sitten selvittää kun jaksaa, kerkiää ja on kiin-
nostunut.” (interview 3) 
 
”When an issue appears, resolving is easier with committed person, who under-
stands that this process will freeze if the issue is not handled and then it has also 
temporal effect. But if there is a CRO outsider it does not matter to that person 
how properly and timely manner things are handled, but she/he resolves them 
when there is time, interest or willingness” (free translation) 
 
Investigators had experienced unfulfilled promises when CRAs have left tasks uncom-
pleted or refuse to complete tasks. Investigators reported that lack of service attitude 
and lack of interest of CRAs complicate work of site personnel. Site personnel have a 
feeling that CRA should not be bothered with the issues. If CRA is only interested in 
her/his own tasks it influences negatively in cooperation. Sometimes CRAs had justi-
fied their unwillingness to do something with rules and regulations. Differences in inter-
pretation of rules and requirements caused friction between investigators and CRAs. 
Investigators had experienced rigid interpretation and meticulousness by monitor. On 
the opinion of one of the interviewees investigators are sometimes falsely blaming 
CRAs for pedantry although it is investigator who has not understood GCP or other 
regulations.  
 
Investigators became annoyed and frustrated when monitor was not able to detect sys-
tematic error in site’s actions on time, especially if it caused lots of extra work or had an 
effect on patient’s eligibility in trial. Investigators also reported that some of the moni-
tors had no understanding for unintended mistakes made by site personnel. Site per-
sonnel received only negative feedback and monitor visited site only in situations 
where site had made something wrong or actions were pending. If site personnel con-
ducted clinical trial satisfactory, site was left alone and not even positive feedback was 
received.  
“Jokainen haluu työstänsä jonkunlaisen palautteen, eikä se palaute voi olla sitä, 
et kun teet väärin niin sit tulee ihminen, joka sanoo: ”Te ootte tehny väärin”. Sit 
kun me on tehty hyvin, ni me ei saada muuta kun tehdä sitä työtämme. Tottakai 
me ollaan tyytyväisiä, et me ollaan tehty oikein asiat ja näin, mut joku vois sen 
kertooki meille.” (interview 1) 
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“Everyone wants to receive feedback and it can´t be so that when we have made 
a mistake then a person comes and says: “You have made a mistake”. And if we 
have performed well, we receive nothing. We just continue our work. Of course 
we are satisfied that we have completed tasks correctly and so, but someone 
could also tell us that.” (free translation)  
 
Investigators understood CRA’s duty to remind them about not completed trial tasks 
but, CRA’s style or attitude to do it may influence negatively on cooperation and inves-
tigator’s motivation. CRA’s style to dictate tasks and duties to site personnel was an-
noying and one investigator reported experience in army like commanding by CRA.     
 
“Ne vaan sit ilmottaa, et tämä pitäis laittaa sinne eikä niinkun se et hei voitaisko 
me yhdessä kattoo tää. Tulee vaan niinku semmonen niinku armeijamainen olo 
”toi on teijän tehtävä, toi on teijän tehtävä, toi on tehtävä, ei mul oo aikaa enkä 
mä saa tulla teille”… (interview 1) 
 
“They just inform that this should be put in there not that can we look at this to-
gether. It feels like in the army: “This is your job, this is your job, this must be 
done, I don’t have time and I’m not allowed to come to visit you” (free translation) 
 
As described in chapter 5.1.1 investigators generally experienced that CRAs were 
reachable but they had also experiences in situations where unavailability had effected 
on cooperation negatively. In conflicts and in situations where CRA was lacking 
knowledge or was not able or willing to ask advices from upper management, investi-
gators had felt that CRAs have avoided contacts. Also if CRA was located in other 
country than Finland reachability was more difficult. Delays in contacts caused uncer-
tainty and unawareness among site personnel.   
 
5.4.2 Site is Left Alone with Increased Workload 
 
The second category in theme “Negative experiences related to cooperation with CRA” 
is derived from six subcategories; Tasks are transferred to sites, CRA is lacking 
knowledge, CRA is not helping, Resolving technical problems is time consuming, Lack 
of personal guidance and Practical training for technology is needed. Interviewed in-
vestigators had noticed that the workload of site personnel has increased. They did not 
necessarily feel trend as deterioration, but as some of the investigators indicated it was 
unfair if in budget negotiation phase of trial, investigator was not aware of all expected 
duties and tasks, but relied on former experiences and some new responsibilities re-
vealed during trial execution phase. 
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“Olin tässä neuvottelussa varmaan niin hölmö, että mä lupasin semmoseen pie-
nempään (palkkioon), koska mä en siinä vaiheessa tienny sitä, että miten paljon 
mun pitää tehdä semmosta ekstra hommaa, jonka monitori on mulle aikasemmin 
tehny” (Interview 6) 
 
“In this negotiation I was so stupid, that I agreed to lower (fee), because in that 
time I didn’t know how much extra work I need to do, work that has previously 
been completed by monitor” (free translation)  
 
It was especially duties and tasks which have previously been performed by CRA that 
have been transferred to the site’s responsibility. Tasks included printing documents, 
ordering supplies, shipping documents and equipment, archiving and resolving tech-
nical issues with helpdesks. Investigators, who had had clinical trials which included 
technical equipment, felt frustration with problems occurring with poorly designed de-
vices. Resolving technical issues took time, increased technologically mediated com-
munication and pressure in cooperation with CRA. Investigators felt that they were left 
alone with dysfunctional devices and there was no local help or guidance available with 
equipment. CRAs guided investigators to contact global helpdesk with the issues and 
investigators were not comfortable to communicate technical problems in English. 
Some of the investigators had experienced that helpdesk had not resolved problem in 
proper time or at all. Investigators hoped to get practical training for technical devices 
and applications. Web-based training and written guidance were not enough. The best 
way to learn was to get personal training from local, competent CRA in their own lan-
guage.  
 
Investigators reported same kind of lacking in local help with other new tasks. Finding 
instructions and guidance were time consuming and there was no help available from 
CRA. CRA’s role was only to monitor that trial responsibilities have been performed 
correctly by site personnel. Lack of help was demotivating as investigators felt that they 
needed to learn everything by trial and error. Some of the investigators expressed their 
concern over inadequate trial data due to lack of guidance. CRA was not able to guide 
or teach because they were also inadequately trained or they were inexperienced.  
 
“Nyt kun sä soitat tommoselle ulkopuoliselle CRA:lle, joka käy täällä kerran, kaks 
ja sit se on vaan niinku puhelimen päässä, sehän sanoo: ”No koittakaa ratkasta, 
jos ette osaa niin soittakaa helpdeskiin. Te ootte tehny nyt jotain väärin, mut mä 
en osaa auttaa”. Eikä ne osaa siis. (interview 1) 
 
“Now when you call to outsider CRA, who visits us ones or twice and then is only 
available by phone, she/he says: “Try to resolve it, if you can’t resolve it call to 
helpdesk. You have done something wrong, but I can’t help you”. And they actu-
ally don’t have the knowledge. (free translation)  
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5.5 Experiences Related to CRO’s Position and Operational Environment 
 
The third category includes experiences related to CRO’s position in between sponsor 
and investigator and generally to operational environment. Although the aim of this 
research is to describe experiences related to cooperation with CRO, some environ-
mental aspects need to be taken into consideration. There were 132 condensed mean-
ings in this category and these were clustered to 20 subcategories and four categories 
(figure 7). 
 
Theme: 
Experiences related to CRO´s position and operational 
environment 
Category: 
1) CRO is 
using sites 
to get prof-
it 
2) CRO-
Sponsor 
contract 
causes dif-
ficulties 
3) CRO´s 
working 
method is 
not satis-
factory 
4) Operational 
environ-
ment influ-
ences in 
cooperation 
Subcategories: 
CRO is treating 
sites as a re-
source 
Handling tasks 
is more difficult 
when CRO is in 
between 
Prior experienc-
es influence in 
willingness to 
participate in 
trials 
Sponsor´s ac-
tions are influ-
encing to gen-
eral picture 
CRO maximiz-
es profit at the 
expense of site 
CRO contract is 
limiting CRA´s 
work 
There are differ-
ences between 
CROs 
Increased CRO 
usage is prob-
lematic 
Unclear duty 
delegation com-
plicates situa-
tions 
Insufficient pro-
cesses in CROs 
increase difficul-
ties 
Challenges in 
operational envi-
ronment influ-
ence in coopera-
tion 
Variation is get-
ting research 
results 
CRO is lacking 
local knowledge 
Handling tasks 
with technology 
has increased 
Development 
need in feed-
back collection 
Technology is 
not utilized 
Amount of fruit-
less work is 
notable 
Same re-
trainings are 
annoying 
Too many 
emails 
High turnover 
rate 
Figure 7. Experiences related to CRO position and operational environment: Themes, catego-
ries and subcategories 
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5.5.1 CRO is using Sites to get Profit 
 
The first category in theme “Experiences related to CRO´s position and operational 
environment” is derived from two subcategories; CRO is using sites as a resource and 
CRO maximizes profit at the expense of site. Some of the interviewed investigators 
experienced that CRO was not treating investigators and other site personnel as equal 
cooperation partners. CRO was focusing on its own interest and utilized site as a re-
source that provides material to CRO and then CRO sells material to sponsor. CRO 
was not so interested in how things are experienced at the trial site. They just wanted 
to use them as mediums to get income and profit. Working directly with sponsor has 
been more like equal partnership. Investigators had understood that CROs have a con-
tract with sponsors to conduct trial for certain sum of money. From that total sum CRO 
was paying investigator and site fees and more they paid, less they gained profit. In-
vestigators understood CRO’s willingness to make profit, but they felt that CRO was 
doing it on expense of site. They had experienced that investigator fees were lower in 
CRO handled trials.  
 
“Semmonen tunne tulee kun näistä siis tutkimuspalkkiosta neuvotellaan niin siinä 
tulee vähän semmonen kuva, et siinä sen tutkijalääkärin osuus niinku minimoi-
tuu, jää niinku pienemmäks. Se CRO-firma vie siitä tietysti tietyn osan. Ja tota se 
on ihan ymmärrettävää, haluaahan he tietysti palkkion itekin.” (interview 4) 
 
“The kind of feeling comes when trial fees are negotiated that investigator’s share 
is minimized, it settles to lower level. CRO-firm takes of course own share and it 
is understandable, of course they also want to have payment too.” (free transla-
tion)  
 
Investigators also indicated that CRO’s profit maximizing made financial agreement 
negotiations more complicated and it was difficult to get compensation for extra work 
needed during the trial, if that was not foreseen during negotiations. Extra work includ-
ed problem resolving, unscheduled patient visits and assessments due to safety rea-
sons and working hours spent to preparations and patient screening. One of the inves-
tigators suspected that CRAs did not always complete all the tasks they were expected 
to complete at site, but they still invoiced sponsor at maximal level.   
 
5.5.2 CRO-Sponsor Contract causes Difficulties 
 
The second category in theme “Experiences related to CRO´s position and operational 
environment” is derived from four subcategories; Handling tasks is more difficult when 
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CRO is in between, CRO contract is limiting CRA´s work, Unclear duty delegation 
complicates situations and Variation in getting trial results. Contract between sponsor 
and CRO concerning clinical trial conduct has an effect also on cooperation between 
CRO and investigator. CRO gets instructions and frames to work from sponsor and 
investigators felt that it was complicated to discuss or negotiate with CRO about the 
issues that were not in CRO’s hands to decide. Financial agreement negotiations were 
typical situations mentioned by investigators. Negotiations were prolonged when CRO 
was in between due to need of CRO to ask every detail from sponsor. Especially if the 
sponsor was located outside of Finland, delays were expected. Cooperation was rigid 
and autocratic also with CROs that had management located outside of Finland.  
 
CRO’s position in between sponsor and investigator and unclear duty delegation be-
tween CRO and sponsor complicated cooperation. Investigators were annoyed if they 
needed to share and explain the same information to both collaborators. It gave an 
idea that it was not clearly agreed between sponsor and CRO who was responsible for 
communicating certain subjects with trial site. Investigators had experiences also in 
situations where decisions were delayed due to uncertainties in responsibilities. Either 
issue was transferred from one person to another and again to another or different per-
sons from CRO or sponsor organization wanted to comment and make arguments to 
the issue and it was unclear who was responsible for the final decision. Resolving is-
sues in that kind of atmosphere was complicated, bureaucratic and time consuming.  
 
“Mä kysyin sitä asiaa monitorilta, monitori kysyi sitten sieltä CRO-firman joltain 
asiantuntijalääkäriltä ja sitten sitä kysytään sieltä sponsorilta, et se niinkun kier-
taa ja kaartaa… Sitten tulee lisäkysymyksiä tulee siltä CRO-ihmiseltä, sitten siltä 
varsinaiselta sponsorilta ja kaikilta siitä välimuodosta, et viis ihmistä laittaa mulle 
meiliä… Sillä tavalla se voi niinkun levitä.” (interview 6) 
 
“I asked from the monitor, monitor asked from CRO´s some kind of medical ad-
viser and then it is asked from sponsor, so it goes around and around… Then 
further questions are presented by CRO-person, sponsor and by everyone else 
in the middle, so five persons were sending me emails… In that way it may get 
around.” (free translation) 
 
The contract between sponsor and CRO has also effect on CRA’s work. Investigators 
indicated that contract defined strictly tasks for CRA and time that CRA was able to 
spent for task completion. Due to agreement CRAs were not able to visit trial site, 
CRAs had no time resources and were only doing tasks they were paid to do by spon-
sor. These experiences have led to situation where investigator need to ensure what 
kind of terms CRA has during the trial before investigator agrees to participate in trial.  
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“Täytyy niinku varmistaa se et miten tää menee tää monitorihomma. Et kummo-
nen ihminen siihen tulee ja mimmoset ehdot sillä on. Tähän saakka on kauheen 
vähän kiinnitetty siihen huomioo, mut näit on ollu näit niin sanottuja ulkopuolisia 
monitorointeja, jotka on voisko sanoo herättäny pientä närää puolin ja toisin niin 
kyl nyt enemmän ja enemmän rupee miettimään” (interview 1) 
 
“We need to ensure how monitoring will go. So who is coming and what kind of 
terms monitor has. Until now we have not paid attention to that, but we have had 
these outsiders’ monitorings that has divided both parties so this needs to be 
taken more and more into account” (free translation) 
 
Sometimes it has been difficult for site personnel to perceive allocation of responsibili-
ties between operators. CRO represents sponsor and CRA may represent CRO which 
is paying her/his salary but CRA also represents sponsor in the trial process. Especially 
in trials where CRA is the only face-to-face contact from sponsor’s site, investigator 
may expect response and involvement in duties she/he is not responsible according to 
CRO-sponsor agreement. This may cause confusion, frustration and conflicts in coop-
eration. 
 
Unfinished contract negotiations between sponsor and CROs have caused extra work 
for investigators. If sponsor had not yet decided to which CRO clinical trial is out-
sourced, different CROs may contact investigator with feasibility assessments concern-
ing the same trial.  
 
In trials where CRO’s responsibility ends before trial is officially closed, investigators 
have experienced confusion especially with archiving. Although archiving site docu-
ments is investigator’s responsibility, investigators felt that they need some guidance 
with it. There was also development need in getting results of clinical trials. Investiga-
tors were interested in to hear about the overall feedback and results of the trial. Alt-
hough receiving results have improved, there were still some delays in it. Investigators 
had noticed that trial closure meeting where results were usually discussed, have not 
been arranged anymore.  
 
5.5.3 CRO’s Working Method is not satisfactory 
 
The third category in theme “Experiences Related to CRO´s Position and Operational 
Environment” is derived from eight subcategories; Prior experience influence in willing-
ness to participate in trials, There are differences between CROs, Insuffisient process-
es in CROs increase difficulties, CRO is lacking local knowledge, Development need in 
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feedback collection, Amount of fruitless work is notable, Too many emails and High 
turnover rate. 
 
Based on experiences of the interviewed investigators, there are differences between 
CROs. Quality in monitoring activities and working method varied between organiza-
tions. Previous experiences related to certain CRO had an effect on willingness to co-
operate with this organization in the future. Overall experience was that turnover rate of 
CRAs was quite high in CROs. Although CRA turnover was not affecting dramatically 
on cooperation as described in chapter 5.1.1, investigators preferred to have the same 
CRA during whole trial process. Some of the investigators thought that a high turnover 
rate was a consequence from poor working climate and lack of team spirit inside CRO. 
In cases investigators were considering participation in clinical trial and had information 
that a certain CRO is conducting the trial, it caused some extra evaluation, but it was 
not primary factor for final decision. Study design and molecule under development 
were more important. But investigators revealed that they had a kind of blacklist of dis-
favoured CROs in mind.  
 
“Jos siitä CRO-firmasta on jotain kokemuksia, mitkä ei oo ollu niin hyviä niin se 
vaikuttaa paljon asiaan. Mut tota jos on semmonen hyvä CRO-firma, josta niin-
kun on ehkä kokemuksia, niin ei se ratkaisevasti silloin vaikuta, mutta aina pikku-
sen se vaikuttaa joka tapauksessa. Et vähän on empivämpi siinä ja se täytyy olla 
se tutkimus muuten mielenkiintoinen ja hyvä.” (interview 4) 
 
“If there are some negative experiences about certain CRO-firm it influences a 
lot, but if CRO-firm has a good reputation, it isn´t decisive, but it influences 
somehow anyway, causes some hesitation and trial need to be otherwise inter-
esting and desirable. (free translation)  
 
Insufficient or inflexible processes inside CROs prevented smooth cooperation. Espe-
cially in big international organizations, where different people are completing different 
tasks there were challenges in continuous information flow inside CRO.    
 
“Siinä firmassa yks hoitaa sopimusneuvottelut, toinen selvittää asioita monitorin 
kanssa, kolmas ihminen ehkä selvittää joitakin ihan käytännön asioita ja näin se 
niinkun leviää kun jokisen eväät… Se tieto ei heillä kulkenu, et esimerkiks sopi-
musneuvottelut katkes yks kaks noin viideks viikoks, joka johtu siitä, että se ihmi-
nen, joka hoiti niitä niin oli sairastunu… nää muut yritti hoitaa niitä omia asioita, 
joita ei voinu hoitaa ku ei ollu sopimusta, et vähän vaikee!” (Interview 6) 
 
”In that firm one person is negotiating agreements, one is handling things with 
monitor, one is figuring out practical matters, so it spreads out… Information was 
not spread. For example agreement negotiations paused suddenly for five weeks 
due to sick leave of negotiator… Others tried to handle their duties but they could 
not do that because there wasn’t signed agreement. It was difficult!” (free transla-
tion)  
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Inflexibility in processes also prevented the usage of meaningful and site specific solu-
tions in cooperation. As example one of the investigators told that in feasibility assess-
ments every investigator receives same kind of multi-page assessment form although 
many questions in form are not suitable or relevant for local practice in Finland. Investi-
gators expressed that CROs were lacking local knowledge and CRO’s actions and 
propositions were based on false assumption. Lack of local knowledge appeared in 
unfamiliarity with local health care and treatment practices, compensation policies, pa-
tient database availabilities and investigator’s motives to participate in clinical trials. 
Some of the investigators experienced that CROs assumed conduction of clinical trials 
to be core task of the investigators and that investigator have countless hours to spend 
for the duties in trial. There were also more fruitless experiences with CROs in trial ne-
gotiations that did not lead to trial agreement than with sponsor. According to investiga-
tors insufficient processes and lack of local knowledge were partially reason for amount 
of fruitless work in cooperation with CRO.  
 
Inflexibility in email communication was also experienced as every message relevant or 
not was sent to the Principal Investigator. One of the investigators indicated that CRO 
outsourced responsibility to investigator by sending email about every minor detail. 
Frustration for increasing amount of emails was mentioned also in other interviews. 
Investigators preferred more targeting in email communication. Investigators hoped to 
have messages only relevant for them and the other messages should be allocated to 
relevant personnel. Investigators were concerned that important messages were lost in 
mass of emails and they were not able to prioritize or evaluate relevancy of every mes-
sage.  
 
“Sitten kun on kymmeniä uusia sähköposteja viikonlopun jälkeen niin sitten tulee 
aina mieleen, et eiks joku vois tän muutenkin hoitaa tän asian… Niihin täytyy 
suhtautua aika niinkun kovalla kädellä sitten siihen, niitä vaan putsataan sieltä 
pois ja siinä saattaa sit joku tärkeempikin viesti mennä ja se on huono juttu, mut 
niitä ei pysty niinkun, jonkun pitäis kuitenkin ne priorisoida, mikä vaatii jotain res-
ponssia ja mikä ei.” (interview 5) 
 
”Then when you have dozen new emails after weekend it always comes in mind 
that could there be some else way to handle this… You need to react in quite a 
hard way and just delete those away and in that process some important mes-
sages may be wasted and that’s bad. Someone should prioritize them, which one 
needs response and which one doesn’t.”  
 
The same kind of targeting was desired for trainings. For an experienced investigator it 
was frustrating and annoying to go through same trainings in the beginning of every 
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trial. Investigators understood need for refreshment training and appreciated if shorter 
version was an option instead of long training sessions designed for beginners.  
 
Investigators were willing to give feedback related to clinical trials. They had given it 
spontaneously especially in situations where a development need was identified. Some 
of the investigators told that they had completed feedback surveys provided by CRO, 
but there has not been systematic feedback collection process in place. Investigators 
experienced that feedback collection and feedback discussions would help to develop 
cooperation and trial processes and were willing to participate in feedback collection. 
They were also willing to obtain feedback about trial site and their own operations. 
 
5.5.4 Operational Environment influences in Cooperation 
 
The fourth category in theme “Experiences related to CRO position and operational 
environment” is derived from six subcategories; Sponsor´s actions are influencing to 
general picture, Increasing CRO usage is problematic, Challenges in operational envi-
ronment influence in cooperation, Handling tasks with technology has increased, Tech-
nology is not utilized and same trainings are annoying.  
 
All of the interviewed investigators had noticed a trend of increasing usage of CROs 
also in Finland. One of the investigators recalled, that in 1990s all of the trials he partic-
ipated in were monitored by sponsor and nowadays all his four ongoing and three com-
ing trials were monitored by CRO personnel. Most of the investigators indicated that 
integrating CROs to clinical trial processes was not successful and it increased prob-
lems. Growth of CRO usage has been a notable change in the field of clinical trials. 
Pharmaceutical companies may achieve financial advantages from outsourcing, but 
investigators thought that it may influence negatively on investigators willingness to 
participate in clinical trials. Many investigators mentioned awareness of decreased 
number of clinical trials conducted in Finland and they were concerned about the trend. 
Personally they had not experienced decrease in clinical trials. They reported that there 
were enough clinical trials available for them.   
 
Sponsor’s decisions and actions have an influence on CRO operations. CRO is repre-
senting sponsor and acting accordance with contract between CRO and sponsor. 
Sponsor’s working methods and guidance determine some kind of frame to CRO oper-
ations and reflect to cooperation between investigator and CRO:  
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“Semmonen yks vähän poikkeava kokemus oli, kun oli “ulkomaalainen” yritys, jo-
ka teki, sponsori oli “ulkomaalainen” ja se jotenki niiden toimintatavat kyllä poik-
kes ihan olennaisesti muista… Mä jotenkin tulkitsin, et se oli sekä sponsorin eri-
laisesta toimintatavasta, että siihen… Kyllä se oli enemmän sponsoriin liittyvä, 
koska siin oli semmonen CRO-yritys, joka on sitten muissa yhteyksissä toiminu 
toisella tavalla, et ei se varmaan ollu siitä CRO:sta kiinni” (interview 5) 
 
“Kind of exceptional experience was when there was a “foreign” company, spon-
sor was from “other country” and its working methods were exceptional com-
pared to others… Somehow I interpreted that it was related to different working 
method of sponsor… Yes, it was more depending on sponsor as the same CRO 
has worked on another way in other trials, so it wasn’t related to CRO.” (free 
translation, country mentioned in interview was masked in quotation)  
 
Although there were negative experiences related to communication with both CRO 
and sponsor prescribed in chapter 5.3.2, some of the investigators experienced that in 
certain situations it is beneficial to have sponsor’s involvement during a trial process. 
Visible involvement generated a feeling of security. Investigators felt that they were 
able to return to sponsor if there were problems with CRO cooperation. Sometimes 
sponsor was involved in problematic issue resolving and that was appreciated.  
 
Strategic decisions of a sponsor have an impact on general view on clinical trial field. 
Investigators had noticed that pharmaceutical companies outsourced trials which were 
strategically unimportant for them. Strategic unimportance may influence on sponsor’s 
motivation to invest on a trial and at site level it has appeared in poor technical solu-
tions, incomplete trial process planning and uncertainty in putting project into effect and 
carrying on as planned. 
 
“Kyllä on tullu vähän vaikutelma, että semmoset sekundääriset hankkeet her-
kemmin ulkoistetaan, jollonka sen niinkun toteutuminen on hiukan epävarmaa. 
Semmostakin on niinku tapahtunu, et on väännetty sopimuksista ja suunnitelmis-
ta tosi pitkään ja sitten vaan yhtäkkiä projekti niinku lopetetaan ja se on tosi tur-
hauttavaa kyllä.” (Interview 5) 
 
”The kind of impression has come that secondary projects are outsourced so put-
ting them into effect is slightly uncertain. It has happened that we have had long 
agreement negotiations and planning and then suddenly project is aborted. It is 
really frustrating. (free translation) 
 
As described in chapter 5.3.3 investigators experienced fruitless work with CRO due to 
internal processes, but sponsor’s operations have also influence on that. Some of the 
investigators indicated that sponsors’ way to invite to bid CROs for trials has an impact 
on amount of fruitless work. As there have been many small companies with high turn-
over rate and without stable relationship with certain sponsor, the knowledge in trials 
and sponsor’s working methods were undeveloped. 
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Investigators indicated also that it is not only the field of clinical trials which has had 
changes and new challenges. They were experiencing increasing challenges also in 
their general practice. In addition to challenges in daily duties, the challenges in a re-
search field were experienced demanding and demotivating. Investigators expressed 
that a successful cooperation was required, appreciated and meaningful in diverted 
and complicated environment.  
 
Investigators had noticed that technologically mediated cooperation has increased. 
Web-based solutions have enabled information sharing in real time and made issue 
resolving possible despite long distance. Technologically mediated solutions have en-
hanced cooperation possibilities and have not decreased communication. 
 
“Ei se (teknologiavälitteinen viestintä) ainakaan vaikeuttanut sitä asiaa (yhtey-
denpitoa) ole, ehkä jopa nopeuttanu joittenki asioitten kohdalla, kun ei se vaadi 
sitä et monitorin pitää matkustaa Helsingistä tänne monta tuntia, vaan me site-
taan ja sanotaan sille ja se sanoo, et se selvittää asiaa ja laittaa viestiä netin 
kautta tai soittamalla niin ei se ainakaan huonontanu sitä sillä tavalla.” (interview 
3) 
 
”It (technologically mediated communication) has not made it (communication) 
more difficult, perhaps even expedited it in some situations, because it is not re-
quired for monitor to travel hours from Helsinki to trial site, but we can call and 
report and monitor says that she/he will resolve the issue and send a message 
via email or call. So it has not at least made communication worse.” (free transla-
tion) 
 
Negative experiences related to technologically mediated cooperation and communica-
tion were concerning increased email communication and described in chapter 5.3.3 
and increased transfer of duties from CRA to investigator including printing electronic 
documents at the site as described in chapter 5.2.2. Investigators also experienced that 
technology has not been yet fully utilized. The development and utilization of electronic 
databases and web-based trainings were mentioned as development needs in the in-
terviews. 
 
”Tällä hetkellä tehdään vähän niinkun sulkakynä-paperisysteemiä vaan sähköi-
sesti monella tapaa, mikä on turhauttavaa” 
 
”At the moment electronic ”guill and paper” system is in use in many ways and 
it’s frustrating.”  (free translation) 
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6 Discussion 
 
Context of this Master´s Thesis is fairly topical issue at the moment. Finland´s national 
public service broadcasting company Yle (2015) released news on 06Apr2015 con-
cerning decreasing number of clinical trials in Finland and its effects on Finnish pa-
tients. Decrease in number of clinical trials decreases quality of health care and pa-
tients´ ability to get novel therapies. Finland is losing frontline position in taking novel 
treatments into the clinical practice. Positive news is slight increase in number of clini-
cal trials in the beginning of year 2015 and this trend was also noticed by investigators 
interviewed for this Master´s Thesis.  
 
The world of clinical trials is international and global. As pointed out in chapter 2.1.1 
global trends are influencing in field of clinical trials in Finland in general and also in 
individual level as results of this research have shown. Although there are differences 
between nations, there are many similarities. For example interviewed investigators in 
Finland shared same kind of primary motivator to participate in clinical trials as their 
colleagues in other countries (Glass 2009); to learn about new medical treatments prior 
to launch.  
 
As the clinical trials are not conducted in isolation, changes in operational environment 
have an influence on circumstances of clinical trial operations. Worldwide financial 
challenges are increasing outsourcing in many other industrial sectors not just in phar-
maceutical industry.  Investigators reported many challenges that are resulted from 
outsourcing clinical trials. Perhaps it is unrealistic and even unnecessary to try to go 
back to “the old times” where sponsors were conducting clinical trials with their own 
headcounts. More important is to focus on improving cooperation between sponsors 
and CROs and also cooperation between CROs and investigators. Based on the re-
sults of this research there are lots of improvement needs and some of them should be 
easily resolved.  
 
Increasing utilization of technology is trend in every sector. There are lots of ad-
vantages in technological solutions usage and all of the technology available is not fully 
utilized yet. In the interviews investigators complained about the need to perform same 
trainings several times and about completing same feasibility assessments. There are 
already many global support-function approaches available that could be time and cost 
saving solutions for all parties. There are web-based trainings where certificate of com-
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pleted training can be uploaded and accessed by multiple study sponsors and cross-
pharma repositories of essential documents and CVs of investigators (Cascade et al 
2015). Sponsors and CROs just need to implement these to their practice. But there 
are also many challenges in technical solutions. Technical problems were causing lots 
of extra work for site personnel in clinical trial sites and help for these issues was not 
always easily available.  
 
Further in this chapter I will discuss research results by focusing on two main themes; 
investigators´ experiences in cooperation with CRAs (6.1) and experiences in coopera-
tion with CROs (6.2). In chapters 6.3 and 6.4 trustworthiness of this research and ethi-
cal considerations are in focus.    
 
6.1 Investigators´ Experiences in Cooperation with CRAs 
 
It was revealed in the interviews that investigators appreciated qualified CRAs and 
were willing to work in cooperation with CRAs. Cooperation only happens if both coop-
eration parties are actively giving their time and resources and sharing goals and re-
sponsibilities (Aira 2012: 50). Investigators valued cooperation with CRAs who have 
time for issue resolving, who were available for contacts and who were seeing clinical 
trial project as teamwork with clinical trial site personnel. Sharing and setting goals to-
gether increased mutual understanding. As Aira (2012) pointed out in her research, 
successful cooperation is created in regular interpersonal interaction by building trust, 
maintaining interpersonal relationships and keeping balance between distance and 
closeness. Results of this research support Aira´s study. Investigators described posi-
tive experiences in cooperation when in the beginning of the trial project CRA visited 
trial site more frequently. Same approach was suggested in Cascade et al (2015) re-
search to reduce feeling of burdensomeness of clinical trials among investigators. Dur-
ing visits investigators were able to familiarize themselves with CRA and trial and were 
able to get confirmation and trust that they were conducting project correctly. Although 
on-site visits were less frequent after study start, built interpersonal relationship was 
maintained by telephone and email contacts and there were no more need for close 
face-to-face cooperation.  
 
Investigators valued CRAs´ competence in clinical trial project management and 
knowledge of medical and medicinal content of the trial. These qualifications are also 
requirements for trial monitor in GCP (1994). Investigators had also experienced that 
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some of the CRAs were lacking knowledge or were not willing to share their knowledge 
with site personnel. As pointed out also in study of Azoulay et al (2010) monitors of 
CROs were lacking “sense of project ownership” and focused rather to individual tasks 
than to the project as a whole. Task orientation may arise from the CRO-sponsor con-
tract. If CRA is trained and appointed to complete only certain tasks but is not involved 
or implemented to whole trial process it is more difficult to see the influence of own 
actions to the whole project. So task orientation is not only grow up from monitors own 
attitude, but also from attitude, guidance and information received from both CRO and 
sponsor.  
 
Workplace relationships are constructed around work related tasks, but in successful 
collaboration goals are achieved and it can be observed in behaviour, satisfaction and 
attitude of collaborators (Aira 2012). Investigators reported that mutual understanding 
was gained by sharing expectations and goals and also by understanding challenges 
each collaborator is facing. Although chemistry between collaborators had influence on 
cooperation, it was more important to investigators that tasks were handled properly 
and businesslike manner rather than close friendship-like relationship with the monitor. 
Similar findings were obtained in Aira´s research. Attitude of the CRAs influenced on 
cooperation and investigators´ motivation to conduct research. CRA´s willingness to 
help and work together with site personnel increased investigators´ motivation to con-
tribute to clinical trials. If CRA was focusing only to her/his own tasks, refusing to assist 
and avoiding communication or using commanding, unkind tone in communication, 
investigators´ motivation was decreased. 
  
6.2 Investigators´ Experiences in Cooperation with CROs 
 
In the research of Azoulay et all (2010) and in global surveys by The Avoca Group and 
Contract Pharma CRO – Sponsor relationships have revealed to be complicated. Busi-
ness orientation of the organizations is different; for sponsor clinical trials are R&D cost 
and income and profit is gained from developed medicines when they are launched in 
to the market. CRO is getting income and profit from the clinical trials. Orientation may 
lead to situation where CRO is using clinical trial sites as resource to get profit and ig-
noring investigators needs, interests and opinions. For a pharmaceutical company in-
vestigator can be a valuable long-time partner as the cooperation continues also after 
drug is on markets.  It should be remembered in sponsor organization that CRO is rep-
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resenting sponsor at the clinical trial site and negative experiences in cooperation with 
CRO may reflect as negative association towards sponsor and its products.   
 
Previous research has showed that lack of embeddedness between sponsor and CRO 
hindered efficient partnership building. It was shown in the results of this Master´s The-
sis that difficulties in sponsor – CRO relationship reflects to CRO - investigator relation-
ship. Contractual stipulations limits CRO´s and CRA´s work, complicates communica-
tion and clinical trial agreement negotiations at least if duty delegation is not clearly 
stated. Lack of commitment among CRO CRAs was influencing negatively on coopera-
tion. Investigators had noticed also high turnover rate among the CRAs in CRO. Being 
embedded in the organization is associated with reduced intention to leave or actual 
leaving (Mitchell – Holton – Lee – Sablynski – Erez 2001: 1118). Embeddedness may 
increase when sponsors are contracting CROs as strategic partners and CRAs are 
included as in-house CRAs in the pharmaceutical company. In-house CRA strategy 
may also increase local knowledge as in-house CRAs are able to increase knowledge 
in sponsor company´s operations, gain benefit from closer teamwork with sponsor rep-
resentatives and utilize knowledge from sponsor´s prior experiences and projects. This 
trend of strategic partnership is increasing and based on the results of this research 
moving to that direction is the correct way.  
 
Nowadays organizations are operating via emails and even though efficiency and ef-
fectiveness of emails are high, there is still need for implementation improvement 
(Sikula – Dodds – Sikula 2012: 8). Investigators were concerned and annoyed about 
enormous amount of email communication from CRO representatives that hindered 
their ability to focus on the relevant information and to notice important messages. 
Based on the results of this research need for implementation improving in emails in 
this context is essential in aspects of cooperation and reliable clinical trial data. Alt-
hough absolute rules for email communication are not available, implementation of 
email etiquette presented by Sikula et al (2012) should be considered. The most im-
portant thing is to send email only to those who need to know of its content. Based on 
description of investigators, emails are sent to everyone and sender is forwarding re-
sponsibility of importance evaluation to receiver. In the initiation phase of the clinical 
trial, discussion about proper email procedures tailored for the site could improve co-
operation and ensure that important and relevant messages are acknowledged at clini-
cal trial site. Also indicating in subject line what the email is about and if the information 
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is important and critical to operations and limited length of email message are crucial 
(Sikula et al 2012). 
 
In the results of Smed and Getz (2013) research lack of systematic feedback collection 
was noticed. The results of this Master´s Thesis support this finding. Lack of regular 
feedback collection prevents development of processes based on lessons learned from 
the prior experiences. Mixed communication process where investigators and other site 
personnel are communicating with many different representatives from CRO and spon-
sor organization hinder the knowledge flow as the representatives may not be aware of 
the information other representatives are giving to and gaining from the site. Investiga-
tors reported failures in internal and interorganizational communication flow in and be-
tween CROs and sponsors. Failures restraining feedback utilization in a process de-
velopment were also reported by Azoulay et al (2010). Although sponsors wanted to 
get feedback from the CROs, information was filtered before it reached applicable per-
sons. There are lots of simple, easy to use feedback collection tools available and im-
plementation of this kind of tools should be taken into consideration for ongoing feed-
back collection in clinical trial operations.    
 
6.3 Trustworthiness 
 
Usage of classic evaluation criteria in qualitative research has several problems. 
Therefore classical reliability and validity was substituted originally by Lincoln and Gu-
ba on 1985 with concept of trustworthiness and it is presented in book of Eriksson and 
Kovalainen (2008: 294). Concept includes four aspects; credibility, transferability, de-
pendability and conformability. I am using concept of trustworthiness in evaluation of 
this research.   
 
Dependability means responsibility of researcher to prove that process of research has 
been logical, traceable and documented (Eriksson – Kovalainen 2008: 294). I have 
described sampling, data collection and analysis process in details in chapter 4. Size of 
sample was only six persons. Group of interviewees was heterogeneous. They repre-
sented different therapeutic areas, were from different towns, clinics and hospitals and 
most of them had experience on clinical trial conduction in different environments in 
private and public health care organizations. The biggest health care organization con-
ducting clinical trials, Hospital District of Helsinki and Uusimaa was left outside from 
this research due to complicated processes of organization. Including this hospital dis-
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trict would have increased credibility of this research. It would have been interesting to 
hear if experiences were still similar. After six interviews in other parts of Finland, satu-
ration was reached and no more interviews were expected to provide new information 
to research topic. 
 
In-depth interview as a data collection method was chosen due to only few prior re-
search concerning phenomenon were available. It would have been too leading to 
choose themes of interview in forehand. To succeed in interview it is recommended 
that interviewees are aware at least of the subject of the interview before the interview 
(Tuomi – Sarajärvi 2013: 73). In an interview request letter to investigators I gave in-
vestigators information about aim and purpose of the research and data collection 
method and also in the beginning of the interview I repeated the information. During 
one of the interviews I sensed that interviewee was expecting more specific questions 
from researcher. In that interview it was more difficult not to lead conversation to cer-
tain topics. Other interviewees had evidently recalled experiences related to CRO co-
operation prior to interview as they spoke more spontaneously about the topic during 
the interview. One of the interviewees was slightly uncomfortable with recording in the 
beginning of the interview but was relaxed eventually. Despite of these experiences in 
my evaluation processes of the research were appropriate and successful.    
 
In evaluation of credibility researcher´s familiarity with research topic and ability to in-
terpret collected data are under focus (Eriksson – Kovalainen 2008: 294). I have eight 
years’ experience in field of clinical trials as a CRA. I have worked in CRO and at 
sponsor so I was already acquainted with the context when I started my research. Dur-
ing research process I was on fulltime study leave, so I was able to take distance to 
CRA´s work. I assume this was the best solution as I was able to make a research as 
an outsider but still had knowledge of context including context specific phrases, roles 
and responsibilities. During analysis process I often thought that it would have been 
difficult for a total outsider to understand meanings of some wordings interviewees 
used, but for me abbreviations and metaphors were understandable. At the end of eve-
ry interview I asked permission to contact interviewees afterwards if I had some ques-
tions concerning content of interview. All the interviewees gave permission, but I did 
not feel the need to ask any further clarifications during analysis process.  
 
Prior to interviews, I considered if former work relationship with most of the interview-
ees would have an influence on the results. After interviews I evaluated former rela-
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tionship to have more benefits than barriers in the final results. Interviewees had trust 
on me from the beginning of the interview so they were able to share their true experi-
ences about the research topic. I did not feel that they were uncomfortable for example 
in revealing negative experiences concerning CRAs because of my background. I tried 
to express my gratitude towards all kinds of experiences and valued their opinions 
without need of criticising. Interview with interviewee I had not former relationship with 
did not deviate from the other interviews and that supported my evaluation on credibil-
ity.  
 
Conformability refers to idea that data and interpretations are truthful (Eriksson - Ko-
valainen 2008: 294). During analysis process I really focused on the idea, that subcat-
egories and categories were describing the original content of the interviews and expe-
riences investigators shared. Before I started to do the reduction of data, I listened to 
the original recordings and read transcriptions several times, so collected data was 
familiar to me. I also went back to original data several times during analysis process to 
ensure analysis was interpreting original data. In chapter 6 I have included some quo-
tations to result presentation so readers may also evaluate that data and interpretations 
are truthful and not just imagination.  
 
Trustworthiness is also evaluated through transferability. Are there connections be-
tween this research and previous research results and also if same kind of similarity 
could be found in other research contexts. (Eriksson – Kovalainen 2008: 294.) Cooper-
ation occurs in many contexts and cooperation has always some context related ele-
ments. Results of this research support previous researches made in clinical trial field 
and about cooperation as discussed in chapters 6.1 and 6.2.  
 
The purpose of the qualitative research is not to make statistical generalization. Pur-
pose is to describe and give theoretically sensible construction for phenomenon. (Tuo-
mi – Sarajärvi 2013: 85) Construction of the cooperation between investigators and 
CROs described in the results of this research is based on experiences of experienced 
investigators. In the interviews I did not define any time period for the experiences. In-
vestigators were able to share experiences during their whole career in clinical trial 
field. In my specifying questions during interview I did not ask them to estimate when 
experiences they described have happened. This may have effected on the results so 
that all of the experiences may not describe the present situation.  
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Other limitation is also connected to interviewees and selection criteria; investigators 
were very experienced in conducting clinical trials. Results are therefore describing 
experiences of experienced investigators and generalization to all investigators is not 
appropriate. As many investigators indicated some of the changes in clinical trial field 
like decrease in amount of monitoring visits or decrease in face-to-face trainings were 
not causing problems to experienced investigators but might do that for inexperienced 
investigators. In future research experiences of inexperienced investigators should be 
also studied to get wider construction of the phenomenon.    
 
6.4 Ethical Considerations 
 
Commitment to ethicality should guide the whole research process and is linked to 
credibility and trustworthy of the research (Tuomi – Sarajärvi 2013: 127). Personal in-
tegrity of researcher may be evaluated from logic of the research process (Eriksson – 
Kovalainen 2008: 72). In this Master´s Thesis I have described research process in 
details in chapter 4 so the reader is also able to evaluate process and logic in it from 
ethical perspective. 
 
Anonymity and privacy of research participants should be the first priority for the re-
searcher and research should not bring any harm to participants (Eriksson – Ko-
valainen 2008: 72-74). I have kept identities of interviewees only in my knowledge. 
Names and places of interviews are documented in signed informed consents and 
those are kept in lockable storage with no access to unauthorized persons. Informed 
consents are stored for one year after research report is finalized and informed con-
sents are destroyed appropriately.  
 
Permissions for interviews were also asked from institutes and companies in which 
investigators were working. Identities of investigators I sent a request for interview were 
not revealed to companies or organizations. Companies and organizations are not 
mentioned in this research report except hospital district of Pirkanmaa as it was re-
quired in permission to research. Investigator interviewed in that hospital district was 
informed about requirement prior interview started and investigator did not feel it harm-
ing. Investigators and my colleagues recommended investigators for the interviews. I 
did not reveal to referees if I had contacted recommended investigators or if they had 
agreed to participate in research.   
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Voluntary participation is an important ethical principle (Eriksson – Kovalainen 2008: 
70-71). Primary contact with investigators was via email when I asked their willingness 
to participate in this research. Investigators were able to choose if they responded or 
not. I did not repeat my request, I did not want to put pressure on investigators that had 
not responded to my enquiry. Those who agreed to participate had an opportunity to 
ask me about the research before they signed the informed consent. They were also 
informed to have possibility to withdraw from the research at any time before research 
report is final.  
 
After I had written first version of result chapter (chapter 6), I sent selected quotations 
to relevant interviewees with short description about the result I have linked quotations 
to via email, so they were able to comment before quotations were published in final 
version of Master´s Thesis. Some strongly dialectical wordings were changed to more 
general language on a request of interviewees, but original meaning or content of quo-
tations were not changed. This procedure increased both anonymity and self-
determination of research participants, but did not have an effect on research results. 
 
7 Conclusions 
 
The purpose of this research was to increase knowledge about cooperation between 
investigators and contract research organizations in the field of clinical trials by describ-
ing how investigators are experiencing cooperation. The objective was to find out what 
kind of positive and negative experiences investigators have in cooperation with CROs. 
There are only few prior researches available about investigators´ experiences and this 
research increases knowledge in this area. Results bring up elements that make coop-
eration positive experience and also reveal development needs in cooperation between 
investigators and CROs.  
 
There is a need for discussion and training inside CRO about working methods with 
trial site personnel. Everyone working in the field of clinical trials should have the same 
goal; to ensure that patients have access to novel, properly developed and researched 
treatments also in the future. Clinical trials should be seen as a cooperative project 
where every actor has their own roles, tasks and responsibilities, but the goal is the 
same and it is achieved only by successful cooperation. In this research only investiga-
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tors experiences were collected. To get overall picture about cooperation between in-
vestigators and CROs, also experiences of CRO representatives should be studied. 
 
As pointed out in chapter 6.3, results of this research reveals experiences of experi-
enced investigators. Interviewed investigators were familiar with clinical trial procedures 
and need for guidance and training for example is different than it is for inexperienced 
investigators. Results might have been different if experiences of inexperienced inves-
tigators were researched or would they? This is the second suggestion for further re-
search.  
 
Based on the results of this research I already made some suggestions in chapter 6 
about development needs with email etiquette and collecting feedback. There is also 
need to evaluate processes inside CROs and between sponsor and CRO to gain more 
streamlined and also more flexible processes for clinical trial operations. Proper pro-
cesses save time and money and can provide a competitive advantage for the firms in 
the high cost and long-lasting drug development process.   
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Letter to Investigators 
 
 
Hyvä Tutkijalääkäri, 
 
Kliinisten lääketutkimusten ulkoistaminen tutkimuspalveluyrityksille (CRO) on 1980-
luvulta alkaen ollut ja on edelleen kasvava suuntaus lääketeollisuuden parissa. Lääke-
yhtiöiden ja tutkimuspalveluyritysten välistä yhteistyötä seurataan erityisesti alan kon-
sulttiyritysten toimesta vuosittain, mutta tutkijalääkäreiden ja tutkimuspalveluyritysten 
välisestä yhteistyöstä on vain niukasti tutkittua tietoa saatavilla. 
 
Teen Metropolia Ammattikorkeakoulussa Helsingissä ylempiin ammattikorkeakoulu-
opintoihin (Master´s Degree Programme in Health Business Management) liittyvää 
opinnäytetyötä tutkijalääkäreiden ja tutkimuspalveluyritysten välisestä yhteistyöstä. 
Tutkimuksen tarkoituksena on saada tietoa tutkijalääkäreiden kokemuksista CRO-
yhteistyöstä. Tavoitteena on kuvata millaisia myönteisiä ja kielteisiä kokemuksia tutkija-
lääkäreillä on yhteistyöstä tutkimuspalveluyritysten kanssa Suomessa. Tutkimuksen 
tuloksia voidaan hyödyntää tutkimuspalveluyritysten toiminnan sekä eri sektoreita 
edustavien terveydenhuoltoalan organisaatioiden kanssa tehtävän yhteistyön kehittä-
miseen. Päättötyötä ohjaa yliopettaja, FT Eija Metsälä (osoite: Metropolia Ammattikor-
keakoulu, Mannerheimintie 172, Helsinki ja puhelinnumero: 050 3478177). 
 
Pyydän Teitä osallistumaan tutkimukseen, koska joko omien tutkimuskoordinaattorina 
(CRA) toimimieni vuosien tai kollegoiltani tai toisilta tutkijalääkäreiltä saamieni suositus-
ten mukaan Teillä on kokemusta tutkijalääkärinä toimimisesta kliinisissä lääketutkimuk-
sissa sekä kokemusta yhteistyöstä CRO:n kanssa. Tutkimukseen osallistuminen on 
täysin vapaaehtoista ja voitte halutessanne perua osallistumisenne missä vaiheessa 
tahansa tutkimuksen aikana. Henkilöllisyytenne ja toimipaikkanne eivät tule muiden 
kuin minun tietooni. Ainoat tutkimusta varten kerättävät taustatiedot ovat sukupuolenne 
ja kokemuksenne kliinisistä lääketutkimuksista vuosina. 
 
Mikäli päätätte osallistua tutkimukseen, pyydän Teitä ottamaan yhteyttä minuun puhe-
limitse tai sähköpostitse (yhteystiedot alla). Tutkimusaineiston keruu tapahtuu noin tun-
nin kestävässä henkilökohtaisessa haastattelussa. Haastattelu nauhoitetaan ja nauhoi-
tukset sekä niistä kirjoitetut kirjalliset versiot säilytetään luottamuksellisesti salasanan 
takana ja tuhotaan vuoden kuluttua opinnäytetyön julkaisemisesta. Haastattelut on tar-
koitus järjestää tammi- ja helmikuun 2015 aikana. 
 
Ystävällisin terveisin 
 
 
Jaana Hynynen 
Puhelin: 040 5243886 
Sähköposti: jaana.hynynen@metropolia.fi 
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Structure of Interviews 
 
Guiding interview questions: 
 In case you are asked to participate as an investigator to clinical trial that has 
feasible protocol and contract research organization is managing the trial, what 
are your thoughts about cooperation with CRO?  
 What kind of positive experiences do you have about cooperation with CRO? 
 What kind of positive experiences do you have about cooperation with CRO? 
 
Haastattelu runko: 
 Jos saatte pyynnön osallistua tutkijalääkärinä kliiniseen lääketutkimukseen, jon-
ka tutkimussuunnitelma on toteuttamiskelpoinen ja tutkimusta hoitaa tutkimus-
palveluyritys, millaisia ajatuksia yhteistyö tutkimuspalveluyrityksen kanssa he-
rättää? 
 Millaisia myönteisiä kokemuksia teillä on yhteistyöstä CRO:n kanssa? 
 Millaisia kielteisiä kokemuksia teillä on yhteistyöstä CRO:n kanssa? 
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INFORMED CONSENT FORM 
 
TUTKITTAVAN SUOSTUMUS 
 
Cooperation between Investigators and CROs – Investigators´ Experiences in 
Clinical Trials in Finland 
 
Minua on pyydetty osallistumaan yllämainittuun tieteelliseen tutkimukseen ja olen saa-
nut sekä kirjallista että suullista tietoa tutkimuksesta ja mahdollisuuden esittää siitä 
tutkijalle kysymyksiä. 
 
Ymmärrän, että tutkimukseen osallistuminen on vapaaehtoista ja että minulla on oikeus 
kieltäytyä siitä sekä perua suostumukseni milloin tahansa syytä ilmoittamatta. Ymmär-
rän myös, että tiedot käsitellään luottamuksellisesti. 
 
 
 
Suostun osallistumaan tutkimukseen:    Suostumuksen vastaanottaja: 
 
 
______________________________ _________________________________ 
tutkittavan allekirjoitus    tutkijan allekirjoitus  
 
 
_______________________________ ___________________________________ 
nimenselvennys    nimenselvennys 
 
 
_______________________________ ___________________________________ 
aika ja paikka   aika ja paikka 
 
